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1.1 INTRODUCTION ON SWINE INFLUENZA 
 
1.1.1 Brief historic overview of influenza 
The Greeks already knew human influenza and a first epidemic was recorded by 
Hippocrates in 412 B.C. The viruses are now classified in the family of the 
Orthomyxoviridae, which has a Greek etymology: orthos meaning “standard, correct” 
and myxo “mucus” (Lamb and Krug, 2001). The name influenza comes from the 
Italian “influenza delle stelle” because in the Middle Ages people believed that there 
was an astrological influence on the disease. Several pandemics stroke the world with 
the “Spanish flu” of 1918 being the most famous (Wright and Webster, 2001). Swine 
influenza was first recognized as a clinical entity in 1918 and its pathology was 
described for the first time by Shope in 1931 (Shope, 1931a). The etiology of this 
disease was first assigned to a bacterium, Haemophilus influenzae suis (Lewis and 
Shope, 1931). Because the intranasal inoculation of bacteria free filtrates of the lungs 
of influenza-infected pigs resulted in mild disease, a viral etiology of the disease was 
suggested. A synergistic effect with H. influenzae suis was presumed since 
inoculation of filtrates together with this bacterium resulted in more pronounced 
symptoms (Shope, 1931b). Today this bacterium is named H. parasuis, the causative 
agent of porcine polyserositis and arthritis or Glässer’s disease (Killian, 1976). The 
viral etiology of human influenza was discovered shortly thereafter (Smith et al., 
1933). The virus was first cultured in embryonated chicken eggs (Burnet, 1936). 
Propagation of influenza viruses in the amniotic cavity of embryonated chicken eggs 
was at first the method of choice since virus replication was supposed to take place in 
the embryo itself (Burnet, 1940). Influenza virus propagation in the membranes 
surrounding the allantoic cavity was demonstrated one year later and turned out to be 
a more practical technique (Burnet, 1941). This method is still the method of choice 
for propagation of influenza viruses for e.g. vaccine production. Influenza virus 
vaccines were developed in the 1940s by the United States military. The first vaccines 
used crude preparations of infected chick embryo tissues or mouse lungs (Francis, 
1953). It is estimated that seasonal influenza in humans causes worldwide about  
250 000 to 500 000 deaths each year. About 250 million doses of influenza virus 
vaccine are marketed each year, requiring hundreds of millions of embryonated 
chicken eggs (Gerdil, 2003). 
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1.1.2 Swine influenza virus: nature and evolution 
Influenza viruses belong to the family of the Orthyomyxoviridae. The members are 
negative, single stranded RNA viruses with a segmented genome, an envelope and a 
diameter of approximately 80-120 nm. There exist 5 genera within the 
Orthomyxoviridae family: type A influenza virus, type B influenza  
virus, type C influenza virus, Thogotovirus and Isavirus 
(http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/fs_ortho.htm). Each of these genera is 
characterized by differences in nucleoprotein (NP) and matrix (M1) proteins which 
are both internal structural proteins. The M2 protein is a minor envelope glycoprotein 
that serves as an ion channel that permits ions to enter the virion during uncoating and 
thus favours genome release. Three RNA-dependent RNA polymerases (PA, PB1 and 
PB2) are important in the replication of the genome. Amongst the RNA viruses, 
influenza is exceptional because replication of the genome takes place in the nucleus. 
Only the non-structural protein 1 (NS1) is expressed during infection while the NS2 is 
a structural protein that functions as a nuclear export protein. Hemagglutinin (HA) 
and neuraminidase (NA) are the main envelope glycoproteins of influenza A radiating 
out of the lipid envelope and they play a role in entry and release of the virus from the 
infected cell, respectively (Lamb and Krug, 2001). A schematic representation of an 
influenza virion is given in figure 1. 
 
 
Figure 1. Structure of an influenza viron. The figure shows the different proteins of 
an influenza virus (adapted from Lamb and Krug, 2001). 
 
(Nucleoprotein) 
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HA and NA molecules are used to classify influenza viruses in different subtypes. 
There are 16 different HA and 9 different NA (Fouchier et al., 2005). These antigenic 
subtypes are distinguished by double immunodiffusion assays with hyperimmune 
animal sera as instructed by the World Health Organization (Assaad et al., 1980; 
Röhm et al., 1996). This classification is reinforced by amino acid sequence 
comparisons, which indicate 40-80% sequence identity between subtypes and about 
90% identity within subtypes (Nobusawa et al., 1991).  
Influenza viruses infect a wide variety of avian and mammalian species. In birds 
all known HA and NA subtypes circulate in at least 82 different combinations (Olsen 
et al., 2006). Avian influenza viruses can be found predominantly in waterfowl, order 
Anseriformes. Passeriformes and Charadriiformes are the other two orders of birds 
from which influenza viruses are mainly isolated (Stallknecht and Shane, 1988). 
Domestic poultry such as chickens, turkeys, ducks, geese, quails, pheasants, ratites 
and caged pet birds are also susceptible to influenza viruses. In poultry there are two 
pathotypes of influenza viruses. The very virulent viruses cause “fowl plague”, now 
termed highly pathogenic influenza (HPAI), and these viruses have a H5 or H7 HA 
with a polybasic sequence inserted at the cleavage site of the HA. The other viruses 
cause a much milder disease, designated low pathogenicity avian influenza (LPAI), 
and can have any HA subtype (Alexander, 1999). In mammals influenza viruses can 
be found in humans, swine and horses and occasionally in other species such as 
felidae and marine mammals. The research in this thesis focuses on swine and 
therefore only this species will be further discussed. 
In swine, different influenza A virus subtypes are present. Currently H1N1, H1N2 
and H3N2 swine influenza virus (SIV) subtypes are endemic in swine in Belgium 
(Labarque et al., 2004). The current H1N1 SIV emerged in the European swine 
population in 1979 and replaced the classical H1N1 viruses (Scholtissek et al., 1983). 
All genes from the current virus are almost identical to those of a duck H1N1 
influenza virus and consequently the H1N1 SIV is called “avian-like” (Brown et al., 
1997). The first isolation of a H3N2 influenza virus in pigs was in Taiwan in 1969 
and the virus is most closely related to the human A/Hong Kong/68 virus. The virus 
has been circulating ever since in swine (Ottis et al., 1982) and disease in pigs was 
first described in 1984. The currently circulating H3N2 SIV originated from a 
reassortment that took place half way the 1980’s, resulting in a virus with internal 
protein genes from the “avian-like” H1N1 virus and HA and NA genes from a 
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“human-like” H3N2 influenza virus (Castrucci et al., 1993). The H1N2 virus is the 
most recent SIV and was isolated for the first time in 1994 in Great Britain from pigs 
suffering from a respiratory outbreak (Brown et al., 1995). Afterwards it was also 
isolated in Italy, France, Belgium, Germany and Spain (Van Reeth et al., 2000). It is a 
“double-reassortant” with HA from a human H1N1 virus from the 1980s, NA from a 
swine H3N2 virus and internal genes from an “avian-like” swine H1N1 virus (Brown 
et al., 1998). Although the same SIV subtypes circulate in Europe, Asia and the 
United States they are antigenically and genetically very different in different 
continents (Olsen et al., 2006). Besides the above-mentioned SIVs, pigs can also be 
naturally or experimentally infected with a wide variety of LPAI viruses and thus the 
pig might play a role in the generation of new pandemic influenza strains (Kida et al., 
1994; Karasin et al., 2004; Van Reeth, 2007; Lee et al., 2009). Serologic evidence for 
highly pathogenic H5N1 avian influenza viruses in pigs was found during the recent 
epizootics of this virus (Choi et al., 2005). A recombinant human influenza virus with 
the NS protein from a HPAI virus resulted in a prolonged virus replication, fever and 
weight loss in pigs. This might in part explain the unusual pathogenicity of HPAI in 
humans (Seo et al., 2002). 
In Belgium and Europe SIVs are very widespread (Maes et al., 1999, 2000; 
Labarque et al., 2004; Van Reeth et al., 2008). The prevalence of farms with 
antibodies to swine influenza in different European countries is very heterogeneous as 
shown in Table 1. The percentage of farms with antibodies to the novel H1N2 SIV is 
generally lower than the percentage of farms with antibodies to H1N1 or H3N2 SIV. 
In Belgium, Germany, Italy and Spain the novel H1N2 SIV has become widespread 
and cocirculates with H1N1 and H3N2 SIV. In the Czech Republic, Ireland and 
Poland, in contrast, both H1N2 and H3N2 SIV are either undetectable or found at low 
levels. The dominant SIV subtype in these countries is H1N1 but its prevalence is 
lower than in the first series of countries. The percentage of influenza seronegative 
farms ranges from only 1% in Belgium to 91% in Poland. A lower pig density or 
differences in the structure of the pig industry might in part explain the lower 
prevalence of swine influenza in some countries (Van Reeth et al., 2008). 
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Table 1. Percentage of farms with antibodies to H1N1, H3N2 and H1N2 swine 
influenza virus in seven European countries (adapted from Van Reeth et al., 2008). 
percentage of farms with antibodies to country 
H1N1 H3N2 H1N2 
percentage of farms 
without SIV antibodies 
Belgium 97 86 89 1 
Germany 94 91 75 2 
Italy 83 68 36 9 
Spain 65 67 87 4 
Czech Rep. 38 5 16 47 
Ireland 42 16 2 44 
Poland 9 0 0 91 
 
 
1.1.3 Swine influenza: pathogenesis, diagnosis and prevention 
Up to 50% of the acute outbreaks of respiratory disease in pigs on commercial 
farms are caused by SIV or by a combination of SIV with bacteria (Loeffen et al., 
1999). Upon infection, SIV is generally limited to the respiratory tract. The main 
target cells are bronchiolar and alveolar epithelial cells. The virus replicates to very 
high levels in the lungs (up to 108 mean tissue culture infectious dose (TCID50) per 
gram of tissue) (Van Reeth et al., 1999; Heinen et al., 2000) and is shed via nasal 
secretions (Van Gucht et al., 2006). Transmission of SIV occurs through nasal virus 
shedding, pig-to-pig contact and aerosol formation. The disease spreads rapidly in a 
herd and virus clearance within an animal takes place within 1 week after infection 
(Van Reeth, 2007). 
Infection with the 3 SIV subtypes results in a clinically undistinguishable disease. 
The incubation period is 1-3 days and disease onset is sudden. Morbidity is high but 
mortality is less than 1% in case of proper treatment against secondary bacterial 
infections. The clinical signs are comparable to those of human influenza and consist 
of fever (rectal temperature higher than 40°C), anorexia, weight loss, lethargy, 
rhinitis, nasal discharge, coughing, sneezing and dyspnea. The animals recover within 
1 week after onset of the disease (Gillespie, 1999; Heinen et al., 2000; Van Reeth et 
al., 2001b; Kitikoon et al., 2006; Olsen et al., 2006). This clinical appearance can be 
observed following both a natural infection and an experimental intratracheal 
inoculation with a high virus dose. Subclinical influenza virus infections occur 
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frequently because most pigs are serologically positive for one or more influenza 
virus subtypes at the end of the fattening period, without observation of clinical 
symptoms of influenza (Maes et al., 1999, 2000; Olsen et al., 2006). 
Macroscopic lung lesions are those typical for a viral catarrhal pneumonia as 
illustrated in figure 2. Lesions consist of dark-red consolidated zones, which are firm 
and not collapsible, visible at the dorsal and ventral side of mainly the apical and 
cardiac lung lobes. The demarcation line between normal and affected lung zones is 
sharp (Gillespie, 1999; Kitikoon et al., 2006; Kothalawala et al., 2006). This pattern is 
seen in both natural and experimental infections and might be caused by the fact that 
the upper lung lobes are easier to reach for the inhaled virus than the lower lung lobes 
in a natural infection or the inoculum in an experimental infection. Microscopically, 
there is necrosis of the epithelia, desquamation of the bronchial epithelial cell layer, 
necrotizing bronchiolitis and bronchointerstitial pneumonia. In early infection stages, 
there is infiltration of neutrophils in the airways and the bronchioles are plugged with 
necrotic debris (Gillespie, 1999; Van Reeth et al., 1999; Heinen et al., 2000). A 
representation of the microscopic lung lesions is given in figure 3. Lymphocytes 
infiltrate in the lungs a few days later. 
 
Figure 2. Typical macroscopic lung lesions (dark-red consolidated zones) in apical 
and cardiac lung lobes after intratracheal inoculation of 106.0 EID50 swine influenza 
virus (H3N2). 
 
A clinical diagnosis of swine influenza is only presumptive since symptoms of 
swine influenza and other respiratory diseases resemble to some extent (Olsen et al., 
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2006). Diagnosis can be done either by virus isolation, detection of viral antigens or 
serological techniques to demonstrate virus-specific antibodies (Janke, 2000). For 
virus isolation nasal exudates or homogenates from post-mortem lung samples taken 
at the acute stage of the infection can be used. Virus isolation can be done either in 
chicken eggs or in cell cultures followed by a hemagglutination test or a staining for 
viral antigens, respectively. Isolation necessitates virus that is not inactivated and thus 
samples must be kept moist and refrigerated. Lungs of influenza infected pigs can be 
used in an immunofluorescence or immunoperoxidase staining to detect viral antigens 
which is conclusive for an ongoing influenza infection. Polymerase chain reaction 
(PCR) tests were also developed for the detection of influenza viruses and the 
different subtypes can be identified by the use of the subtype specific primers HA1, 
HA3, NA1 and NA2 (Choi et al., 2002; Lee et al., 2008). The PCR can be performed 
on a wide range of samples including nasal swabs, lung tissue or cell culture isolates. 
Currently, the PCR test is rather expensive and therefore it is used more for research 
than for diagnostic purposes. Serodiagnostic techniques for swine influenza are 
discussed in Chapter 1.2.2. 
 
 
Figure 3. Typical light microscopic lung lesions visible with a hematoxylin and eosin 
staining (alveolar damage and necrotic debris in bronchi) 24 h after intratracheal 
inoculation of 106.0 EID50 swine influenza virus (H3N2). 
 
Prevention and control of swine influenza mainly consists of vaccination. Vaccines 
contain a representative of a H1N1 and a H3N2 SIV. Vaccines that also contain the 
more recent H1N2 SIV are not yet licensed in Belgium. The vaccine strains used in 
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Europe and the United States differ because of different SIV strains circulating in 
both continents (Olsen et al., 2006). In Belgium the licensed SIV vaccines contain the 
older human A/New Jersey/8/76 (H1N1) or the porcine Swine/Netherlands/25/80 
(H1N1) and A/Port Chalmers/1/73 (H3N2). The A/New Jersey/8/76 H1N1 strain is 
included in the SIV vaccine from Merial (Gripovac®). The sw/Netherlands/25/80 
H1N1 SIV is included in the SIV vaccine from Fort Dodge A.H. (Suvaxyn Flu®). 
Although the strains used in the SIV vaccines differ antigenically from the currently 
circulating porcine influenza viruses (de Jong et al., 1999), the vaccines can still offer 
an outstanding clinical and virological protection. In vaccination-challenge studies, 
protection of pigs against SIV challenge is correlated with the pre-existing titre of 
serum hemagglutination inhibition (HI) antibodies and the protection is better after an 
intranasal than after an intratracheal challenge (Heinen et al., 2001; Van Reeth et al., 
2001a; Van Reeth et al., 2001b). 
The economical significance of swine influenza and the cost-benefit of vaccination 
against swine influenza have not yet been thoroughly studied. The retarded weight 
gain resulting in an increase in the number of days to reach market weight is probably 
the most important economic repercussion of swine influenza (Heinen et al., 2001). 
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1.2 THE SEROLOGICAL DIAGNOSIS OF SWINE INFLUENZA 
 
1.2.1 Humoral immune response after swine influenza virus infection 
The immunity consists of the innate immunity, which includes amongst other 
things IFN-α, and the adaptive immunity. The humoral immune response is part of 
the adaptive immunity against many pathogens including influenza viruses. In 
contrast to the innate immunity, the adaptive branch of the immune system has a high 
specificity for the offending pathogen and it has a memory. A principal component of 
the humoral immune system is the plasma cell, which produces antibodies against 
pathogens. When bone marrow derived B-cells are activated by antigen recognition 
and T-helper cells they evolve into antibody secreting plasma cells or form a pool of 
memory cells. Antibodies are a heterogeneous family of proteins in the body and they 
account for approximately 20% of the plasma proteins. A typical mammalian 
antibody molecule consists of 2 identical heavy and 2 identical light chains. There are 
5 different classes of immunoglobulins (IgG, IgA, IgM, IgD and IgE) based on 
differences in the heavy chains. IgG is the predominant antibody class in serum. IgM 
is a pentamer of 5 antibodies and is the first antibody class that is secreted after an 
infection. IgA is secreted in mucosal secretions as a dimer of 2 immunoglobulins 
connected by a J chain. Antibodies contribute to the elimination of a viral infection by 
1) binding to, followed by destruction of, infected cells and 2) binding with released 
progeny virus which inhibits the spread of the infection, termed virus neutralization 
(Goodman, 1991).  
The humoral immune response induced by a SIV infection has been studied 
extensively. Most antibodies produced during a SIV infection are directed against the 
HA, NA, NP and M protein. Antibodies to the HA can block attachment of the virus 
to the host cell receptors and thus neutralize viral infectivity. Antibodies to the NA, 
NP and M proteins cannot prevent the initiation of infection, but they can mediate 
destruction of infected cells and antibodies to the NA also interfere with the release of 
virus particles from an infected cell (Olsen et al., 2006). After a primary SIV 
infection, antibodies of the IgM isotype are first produced followed by IgG antibodies 
(Kim et al., 2006). IgM antibodies are undetectable one month after infection whereas 
IgA and IgG antibodies are still present. In this way detection of IgM antibodies could 
be used as an alternative method instead of paired sera for the serological diagnosis of 
a recent SIV infection (Lee et al., 1995; Heinen et al., 2000). Hemagglutination 
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inhibiting antibodies in serum can be detected starting from 1 week after infection, 
peak at 2-3 weeks after infection and decline from 8 weeks after infection (Heinen et 
al., 2000; Van Reeth et al., 2006). Using a sensitive immunoperoxidase monolayer 
assay (IPMA) test, antibodies were detected in serum as early as 3 days post 
inoculation (Direksin et al., 2002). In several studies the local antibody response in 
broncho-alveolar lavage fluid (BALF) and nasal lavage fluid (NLF) of experimentally 
SIV inoculated pigs was compared with the serum antibody response. IgA was the 
predominant antibody isotype in both BALF and NLF whereas IgG was the 
predominant antibody isotype in serum (Heinen et al., 2000; Larsen et al., 2000; 
Kitikoon et al., 2006). Larsen et al. (2000) could demonstrate antibody-secreting cells 
in nasal mucosal tissue, which proves that antibodies are also locally produced in the 
respiratory tract of pigs.  
 
1.2.2 Tools for serological diagnosis of swine influenza 
Since clinical symptoms and lesions of swine influenza are not pathognomonic, 
laboratory testing is required to confirm diagnosis. Different diagnostic tools are at 
our disposal as reviewed by Janke (2000) and discussed in Chapter 1.1.3. Although 
virus isolation is the most accurate diagnostic technique for detection of an ongoing 
influenza virus infection in swine, serologic techniques might still be useful for 
laboratories that do not have the possibilities for cell culture or incubation of eggs, for 
determination of the immunological status of swine against SIV, to optimize 
vaccination schedules and for seroprevalence studies. Serological data, however, are 
difficult to interpret because of antigenic differences between the SIV strain that 
infected the pig and the SIV strain used in a serological test. For serological diagnosis 
of SIV, the use of paired acute and convalescent sera, 3 to 4 weeks later, is necessary. 
Since the acute serum might already contain antibodies from earlier infections or 
vaccination, only a four-fold or higher rise in antibodies in the convalescent serum is 
conclusive for the diagnosis. The HI test, virus neutralization (VN) test, IPMA and the 
enzyme-linked immuno sorbent assay (ELISA) are the most commonly used tests to 
detect SIV specific antibodies and will be briefly discussed below. The properties of 
the different serological tests are summarized in Table 2. 
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Table 2. Strengths and weaknesses of the current serological tests for the detection of 
antibodies against swine influenza virus. 
characteristic HI(1) VN(2) IPMA(3) ELISA(4) 
sensitivity ++ +++ ++ - 
subtype specificity ++ ++ - +/- 
convenience + - + +++ 
correlation of titre with protection ++ ++ - - 
labour intensive + ++ + - 
suitable as standard test +++ + - - 
+++: very high, ++: high, +: moderate, +/-: depends on test kit, -: low  
(1) hemagglutination inhibition test, (2) virus neutralization test,  
(3) immunoperoxidase monolayer assay, (4) enzyme-linked immuno sorbent assay,  
 
The HA of influenza viruses can bind to red blood cells (RBC) of mammalian or 
avian origin and this property is used in the HI test. Consequently, this test detects 
antibodies against the HA of the virus. Serum samples have to be pretreated by 
adsorption to RBC to remove non-specific agglutinins and by receptor destroying 
enzyme from Vibrio cholerae to inactivate non-specific inhibitors of the 
agglutination. Next, serum samples are serially 2-fold diluted, 4 hemagglutinating 
units of influenza virus are added, and the mixture is incubated for one hour. A RBC 
suspension is added and one hour later HI titres can be recorded. The HI titre is the 
reciprocal of the last sample dilution that completely inhibited hemagglutination 
(Webster et al., 2005). The HI test is very accurate and is the “gold standard” for 
serodiagnosis of swine influenza. Critical in this test is the antigenic agreement 
between the SIV strain used in the test and the SIV strain against which antibodies are 
detected. This can be a disadvantage when it is important to detect antibodies against 
any SIV but it is an advantage for seroprevalence studies to know which subtypes and 
strains are circulating in the population. Separate HI tests against representatives of 
the predominant subtypes endemic in the region of sampling have to be performed. In 
the European situation this requires 3 HI tests with representatives of H1N1, H3N2 
and H1N2 SIV. The HI test can adequately discriminate between European H1N1, 
H3N2 and H1N2 SIV since they have antigenically different HAs (Van Reeth et al., 
2006). In the United States the situation is different because the American H1N1 and 
H1N2 SIV share a similar “classical” H1 and the HI test can not discriminate between 
both (Long et al., 2004). 
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The VN test is very labour intensive and technically complicated but very suitable 
for the detection of antibodies against influenza viruses (Benne et al., 1994). Serially 
two-fold diluted heat inactivated serum samples are made in duplicate and incubated 
with a standardized amount of virus prior to the addition to Madin-Darby Canine 
kidney (MDCK) cells. The neutralization can be detected after 3-4 days of incubation 
by the presence of cytopathogenic effect (CPE) under an inverted light microscope. 
The VN titre is the reciprocal of the dilution where 50% of the wells shows CPE 
(Webster et al., 2005). For neutralization of 1 infectious influenza virion about 70 
antibody molecules are necessary (Outlaw and Dimmock, 1991). The VN test detects 
antibodies against the HA since such antibodies prevent infection of the cell and 
consequently VN titres are correlated with protection against disease. The VN test has 
advantages over the HI test since it is more sensitive (Gross and Davis, 1979). The 
VN test is time consuming because CPE can only be read several days after the virus-
antibody mixture has been inoculated on the cells. This incubation period can be 
shortened when infection of the cells is judged by an immunoperoxidase staining after 
only 1 day of incubation in stead of the appearance of CPE (Okuno et al., 1990). The 
antibodies used for such staining have to recognize the influenza virus strain used in 
the test, and to circumvent this problem, monoclonal antibodies against the conserved 
NP are useful (Kim et al., 2006). 
The IPMA, which is rarely used for the serodiagnosis of SIV, is an influenza 
subtype unrestricted test. In this test, MDCK cells in 96-well plates are infected with 
influenza virus, incubated for a few days and fixed with ethanol. Plates can be stored 
at -20°C until use. Next, dilution series of the serum samples are added and following 
incubation a peroxidase-labelled anti-swine antibody is added. The reaction is 
visualized by addition of a substrate. The IPMA titre is the reciprocal of the highest 
dilution with positive cells. The test probably detects antibodies against NP because 
the IPMA yields light microscopically the same picture of a cytoplasmatic staining as 
a staining with a monoclonal anti-NP antibody of influenza infected MDCK cells. 
IPMA titres are not correlated with protection against disease. This test is positive 
earlier than the HI test, at 3 versus 7 days post inoculation, and IPMA titres are higher 
than HI titres (Direksin et al., 2002). Another advantage of the IPMA test is that sera 
do not have to be pretreated as in the HI test. IPMA tests can also be used to detect 
different isotypes of antibodies by adapting the secondary antibody in the test. 
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Several commercial ELISA kits are marketed in Europe. Depending on the 
manufacturer they can be subtype specific and detect antibodies against H1N1 or 
H3N2 SIV. Often these kits are of American origin and it was not known at the start 
of this research whether they could also detect antibodies against the H1N1 and H3N2 
SIV strains circulating in Europe. An ELISA principle used in other kits is the 
detection of antibodies against NP. These kits detect antibodies against all SIV 
subtypes and are species unrestricted (Kim et al., 2006). ELISAs for NP antibodies 
were originally developed for the detection of antibodies against avian influenza 
viruses but some are also validated for the detection of antibodies against SIV. 
Serological tests do not allow to differentiate between antibodies induced by 
infection or vaccination although one study shows that this differentiation can be 
made by an ELISA based on the NS1 protein against which antibodies are present in 
infected pigs but not in vaccinated pigs, but such test is not yet commercially 
available (Kim et al., 2006). 
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1.3 IFN-α AND OTHER CYTOKINES WITH A ROLE IN THE PATHOGENESIS OF SWINE  
INFLUENZA 
 
1.3.1 Brief introduction on interferon 
Interferon (IFN) was first discovered by Isaacs and Lindenmann (1957). They 
observed that incubation of heat-inactivated influenza virus with chicken chorio-
allantoic membranes resulted in the release of a factor that interfered with the growth 
of live virus. Hence, this factor was named interferon. A correlation was found 
between the IFN concentration and its ability to suppress the growth of influenza 
virus (Isaacs et al., 1957). Interferons are a broad family with many members. They 
are classified as type I or type II IFN (Sen and Lengyel, 1992) or type III IFN. Type I 
IFN (virus-induced IFN) contains IFN-α, IFN-β, IFN-ω, IFN-κ, IFN-δ, IFN-ε and 
IFN-τ. IFN-α and IFN-β were originally named leukocyte and fibroblast IFN because 
the hypothesis was that these cells were the main producers of IFN-α and IFN-β, 
respectively. The porcine IFN-α multigene family contains 14 functional IFN-α genes 
and 2 IFN-α pseudogenes (Cheng et al., 2006). In contrast with IFN-α, there is only 1 
IFN-β subtype (Artursson et al., 1992). IFN-γ is the only representative of type II IFN 
(immune IFN). Type III IFN was described more recently and comprises IFN-λ1 (IL-
29), IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B) (Kotenko et al., 2003). Type III IFN is 
also induced upon virus infection or by type I IFN and is regulated by the same 
mechanism as IFN-α/β (Onoguchi et al., 2007). IFN-α and IFN-β have a strong 
antiviral activity whereas IFN-λ and IFN-γ have a limited antiviral activity (Ank et 
al., 2006). Type I IFNs other than IFN-α/β, play ill-defined roles such as establishing 
uterine receptivity to implantation in mammals (Bazer et al., 2008). 
 
1.3.2 Induction of IFN 
Type I IFN is produced by virus infected cells. Virus specific RNA (5’ 
triphosphate moieties of single-stranded RNA and double-stranded RNA) is 
recognized by the cell as non-self and initiates interferon production (Bowie and 
Fitzgerald, 2007). The intracellular cascade for IFN induction is complex and 
induction of IFN-β is best understood. This process involves IFN regulatory factors 
(IRF) or nuclear factor kappa B (NF-κB). These factors migrate to the nucleus upon 
stimulation where they bind to a promotor of the IFN-β gene that is activated and 
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transcripted and subsequently IFN-β protein is synthesized and released from the cell 
(Haller et al., 2007; Randall and Goodbourn, 2008). 
 
1.3.3 Intracellular signalling and the antiviral effect of IFN-α  
Both IFN-α and IFN-β bind to a common heterodimeric type I IFN receptor, 
consisting of two subunits: IFNAR1 and IFNAR2 (Kim et al., 1997). One subunit of 
the receptor binds with tyrosine kinase 2 (TYK2) and the other subunit with a janus 
kinase (JAK1). After binding of IFN on its receptor, these kinases phosphorylate both 
subunits of the receptor. Next, signal transducer and activator of transcription (STAT) 
1 and 2 are phosphorylated and form a dimer that is transported to the nucleus. The 
dimer associates with IFN regulatory factor-9 (IRF-9) and subsequently the complex 
binds to IFN-stimulated response elements (ISRE) located in the promotors of IFN-
responsive genes. In this way, several hundreds of genes are up-regulated (Randall 
and Goodbourn, 2008). This pathway is schematically represented in figure 4. 
 
Figure 4. IFN-α signalling cascade (explanation see text). Binding of IFN-α to its 
receptor activates an intracellular cascade, leading to the production of antiviral 
proteins (PKR, Mx and OAS). 
 
Some of the proteins induced by this pathway have an antiviral activity. The best 
characterised are protein kinase R (PKR), 2’,5’-oligoadenylate synthetase (OAS) and 
orthomyxovirus resistance (Mx) protein. Probably there are still other antiviral 
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pathways since mice with a targeted disruption in these three genes still have a limited 
antiviral activity against encephalomyocarditis virus (Zhou et al., 1999). PKR is 
synthesised in cells in an inactive form. After virus infection of the cell, PKR is 
activated by dsRNA (Clemens, 1997). In its active form it phosphorylates eukaryotic 
initiation factor 2 (eIF-2), resulting in inhibition of protein synthesis (Rhoads, 1993). 
Another gene that is up-regulated by the IFN signalling pathway is OAS. OAS 
activates RNase L that cleaves within ssRNA, such as viral mRNA. Since RNase L 
has a higher affinity for viral RNA than for cellular RNA (Li et al., 1998), viral 
protein synthesis is inhibited (Silverman, 2007). The third major antiviral protein is 
Mx. The exact mechanism of action of Mx is not yet fully understood (Lee and Vidal, 
2002; White and Sen, 2009). Mx protein is a GTPase that belongs to the superfamily 
of dynamin-like GTPases. Probably Mx blocks viral nucleocapsid transport or viral 
RNA synthesis, depending on whether Mx is present in the cytoplasm or in the 
nucleus (Samuel, 2001). There are two Mx proteins in mice: Mx1 and Mx2. Mx1 is 
indispensable for the recovery from influenza in mice and Mx2 is involved in the 
resistance against vesicular stomatitis virus (Staeheli et al., 1986; Zürcher et al., 
1992). In influenza virus-susceptible mice, the Mx1 gene is defective and most inbred 
strains, such as BALB/c mice, carry non-functional Mx1 alleles, which is probably a 
founder effect (Staeheli et al., 1988). In humans the homologous genes are MxA and 
MxB. In pigs, 2 homologous proteins were also identified and named Mx1 and Mx2 
(Müller et al., 1992). Cells expressing porcine Mx2 protein had a two-fold reduced 
titre of progeny virus meaning that porcine Mx2 possesses antiviral activity against 
influenza (Morozumi et al., 2009). 
 
1.3.4 Systemic effects of cytokines with emphasis on IFN-α  
During bacterial infections some components of the bacteria, such as the cell-wall 
component lipopolysaccharide (LPS) or endotoxin of Gram-negative bacteria exert 
toxic effects on themselves. Synergistic effects of bacterial LPS and porcine 
reproductive and respiratory syndrome virus (PRRSV) or porcine respiratory 
coronavirus (PRCV) in disease induction have also been described (Van Gucht et al., 
2003). Therefore, respiratory viruses, together with bacteria, play an important role in 
multifactorial respiratory disease (Van Gucht et al., 2004). Viruses, like influenza, do 
not possess such toxins although in earlier days a direct toxic effect of influenza 
viruses in mice was assumed (Henle and Henle, 1946a; Henle and Henle, 1946b). 
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Toxic effects of viruses on the body are thus indirect by apoptosis of infected cells 
(Herold et al., 2008) and the induction of cytokines. The latter was discovered in 1974 
when it was found that a flu-like syndrome in different animal species could be 
induced by injecting dsRNA, an intermediate in the replication of viruses that induces 
IFN-α (Carter and De Clercq, 1974). 
The effect of IFN-α on the body has been investigated by injection of IFN-α 
preparations in animals, human volunteers or cancer patients. One of the main effects 
of IFN-α is the induction of fever (Dinarello et al., 1984; Kurokawa et al., 1996). 
Other effects include chills, myalgia, malaise, headache, fatigue and anorexia (Scott et 
al., 1981; Gutterman et al., 1982; Segall and Crnic, 1990; Corssmit et al., 1995). A 
remarkable difference between humans and mice after administration of IFN-α is that 
humans develop fever while mice do not. This difference is also seen in influenza 
infections in humans or mice (Valentine et al., 1998). IFN-α also has an effect on the 
cell profile in the blood: after intramuscular or subcutaneous injection it induces a 
transient rise in neutrophil counts (Scott et al., 1981; Corssmit et al., 1997). 
Other cytokines generate clinical effects comparable to IFN-α. Interleukin-1 (IL-1) 
for example induces fever, reduced food consumption, weight loss, decreased libido, 
sleepiness and a decreased locomotor activity (McCarthy et al., 1985; Swiergiel et al., 
1997; Larson and Dunn, 2001). Some cognitive functions may also be affected 
(Larson and Dunn, 2001). Also tumour necrosis factor (TNF) causes anorexia and 
consequently weight loss. This effect has been well described in mice treated with 
TNF (Bernstein, 1996). Conversely, another study showed a small effect of a 
combined treatment with TNF binding protein, anti-IL-6 monoclonal antibodies and 
IL-1 receptor antagonist resulting in a not significant reduction in food consumption 
in influenza-inoculated mice (Swiergiel and Dunn, 1999). TNF and IL-6 also play a 
role in fatigue in cirrhosis patients (Albillos et al., 2006). The general effect of TNF, 
IL-1 and IL-6 is to induce classic illness behaviour, including somnolence, apathy, 
fever, and anorexia. Hepatic production of acute phase proteins is a characteristic of 
many inflammatory conditions and mainly IL-6, TNF and IL-1 induce the production 
of these proteins (Murch, 1998). 
The fever and the behavioural changes caused by cytokines are supposed to be a 
“highly organized strategy that is at times critical to the survival of the individual if it 
were living in the wild” (Hart, 1988). The fever increases the efficacy of the host’s 
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immune system and the behavioural changes drive the animal to hide and remain safe 
while the immune system clears the invading pathogen (Hart, 1988). The mechanisms 
by which cytokines exert their systemic effects are not completely understood. 
Cytokines can penetrate the blood-brain barrier by saturable transport systems capable 
of transferring the cytokines IL-1, IL-6 and TNF from the blood to the brain tissue 
and consequently these cytokines could affect the brain function (Banks et al., 1995). 
IFN-α has also been found on sites such as the hypothalamus and the pons, where the 
blood-brain barrier is more permeable (Dafny and Yang, 2005). A third possibility is 
that cytokines induce secondary mediators in the organ where they are produced and 
that these are capable of crossing the blood-brain barrier or alternatively cytokines 
could stimulate afferent branches of the Nervus vagus (Katsuura et al., 1990; Netea et 
al., 1999; Dantzer, 2001). Cytokines produced locally in infected organs mainly exert 
effects at the site where they are produced. When massive amounts of cytokines are 
produced there can be a spill-over into the circulation with possible systemic effects 
(Openshaw, 2004; Barbé et al., 2009). 
 
1.3.5 Studies on the role of IFN-α  in the mouse model of influenza 
IFN-α is an important cytokine that is part of the innate immunity against virus 
infections. IFN-α induces an antiviral state in cells and thus provides an early defence 
mechanism against many viruses. This property can also be used in bioassays to titrate 
the amount of bioactive IFN-α present in different biological samples (Meager, 2003). 
Traditionally, the laboratory mouse is used as a model to study the pathogenesis of 
influenza. Our knowledge about the effect of IFN-α on the pathogenesis is to a large 
extent based on the use of mice or cell cultures. Different tools can be used to this 
purpose, e.g. a wide variety of neutralizing antibodies, knock-out animals or cell lines. 
The main disadvantage of these approaches is that mice are not natural hosts for 
influenza viruses and consequently mouse-adapted influenza viruses, like the 
A/PuertoRico/8/34 influenza strain, have to be used. Cell lines are easier to 
manipulate than animals but they are hardly relevant for the in vivo situation. 
The profile of IFN-α during a murine influenza infection is well known. While the 
reaction of the body following a bacterial or viral infection is often clinically 
indistinguishable, only IFN-α is typically associated with viral disease (Gendrel et al., 
1999). The interferon inducing capacity of influenza viruses in the lungs of influenza-
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inoculated mice is already known for a long time. IFN is produced early after 
influenza infection. Several studies show maximal lung tissue levels of IFN between 2 
and 4 days after intranasal inoculation of influenza and the peak of IFN is 
accompanied by maximal virus titres (McLaren and Potter, 1973; Wyde et al., 1982). 
Also tracheo-bronchial washings and BALF of influenza inoculated mice show a 
similar IFN profile and these samples also contain several other cytokines, such as  
IL-1α, IL-1β, IL-6, TNF, IFN-γ and granulocyte-monocyte colony stimulating factor 
(GM-CSF), which show the same profile as IFN (Iwasaki and Nozima, 1977; 
Vacheron et al., 1990; Hennet et al., 1992; Conn et al., 1995; Peper and Van Campen, 
1995). TNF is a key mediator of lung lesions since treatment with TNF antibodies 
ameliorated gross and histological lung lesions but did not affect influenza lung virus 
titres (Peper and Van Campen, 1995). The main cytokine producing cells in an 
influenza infection appear to be monocytes/macrophages as reviewed by Julkunen et 
al. (2000). 
Administration of IFN-α neutralizing antibodies is an adequate technique to gain 
more insight on the role of IFN-α in the pathogenesis of viral infections. This is an 
approach that was already used about 30 years ago in encepalomyocarditis, herpes 
simplex, vesicular stomatitis, Newcastle disease or influenza virus inoculated mice 
(Gresser et al., 1976a; Gresser et al., 1976b; Hoshino et al., 1983). In these studies a 
partially purified sheep antiserum that was obtained after immunization of sheep with 
a crude mouse interferon preparation was used. Results of both studies were not 
univocal. In the study of Gresser et al. (1976b) intravenous administration of the 
interferon antiserum in intranasally influenza inoculated mice did not influence the 
course of the disease. In the study of Hoshino et al. (1983), in contrast, mice were 
inoculated with influenza virus by aerosol and the interferon antiserum was 
administered intranasally. In this case the antiserum treated animals survived whereas 
control animals died and antiserum treated animals had higher lung virus titres. The 
seemingly contradictory findings of both studies suggest that the inoculation route of 
the virus and the way in which the interferon antiserum is administered are critical for 
the outcome of the influenza infection in mice. 
More recently, mice deficient in the type I IFN receptor became available. This 
approach has an advantage over the use of IFN neutralizing antibodies in that the 
effect of all type I IFNs is blocked. But even in this system the overlap or redundancy 
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of the effect of different cytokines cannot be prevented. Type I IFN receptor knock-
out animals did not show major differences with wild type animals regarding lethality, 
virus replication, kinetics of the cellular immune response or the ability to maintain an 
effective recall cytotoxic T-cell response to heterosubtypic challenge (Price et al., 
2000). The same receptor deficient mice were also used in a study that focussed on 
the body temperatures and sleep responses in influenza inoculated animals. Results of 
that study indicated that type I IFN slightly ameliorates disease symptoms early in 
infection while exacerbating symptoms later in the infection (Traynor et al., 2007). 
Inoculation of mice deficient in the STAT1 protein resulted in systemic infections and 
higher mortality (García-Sastre et al., 1998). 
 
1.3.6 Pigs as a model for human influenza 
Bacterial or viral respiratory tract infections occur with a high prevalence in swine, 
and many commensal bacteria that can induce cytokines harbour in the respiratory 
tract. Moreover, healthy conventional pigs can have basal levels of cytokines such as 
TNF or IL-1 in BALF (Van Reeth et al., 1998). Therefore the use of caesarean-
derived colostrum-deprived (CDCD) pigs raised under sterile conditions is necessary 
for the in vivo study of the role of cytokines in respiratory infections in swine. CDCD 
piglets at the age of 3 weeks are fully capable of cytokine production and are also 
most suitable from a practical viewpoint (Van Reeth et al., 1998). 
Intratracheal inoculation of influenza virus seronegative pigs with a high virus dose 
(107.5 mean egg infectious dose (EID50)) results in typical swine flu symptoms, 
fulminate lung virus titres and high levels of proinflammatory cytokines in BALF, 
including IFN-α, IL-6, IL-1, and TNF. Afterwards there is a decline and 
normalisation of these parameters (Van Reeth et al., 1999; Van Reeth et al., 2002b). 
For a respiratory infection like SIV the best specimen for the determination of 
cytokines is BALF since this sample contains the highest cytokine levels as compared 
to serum or the lung tissue (Barbé et al., 2009). Intranasal influenza inoculation leads 
to a much milder disease with less symptoms, lower lung virus titres and lower 
cytokine levels. Vaccination against SIV can greatly reduce or prevent virus 
replication, induction of cytokines and disease (Van Reeth et al., 2002a). This leads to 
the hypothesis that massive replication of SIV induces high levels of cytokines in the 
lungs and that these cytokines are responsible for disease symptoms, as is also stated 
by other authors (Majde, 2000). 
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Macrophages in an influenza infection are responsible for apoptosis of epithelial 
cells and are responsible for alveolar damage in murine and human models of adult 
respiratory distress syndrome (Herold et al., 2008). Both IFN-β and TNF potentiate 
virus-induced apoptosis, which may prevent infection and replication in surrounding 
cells because they are dying (Brydon et al., 2005). Macrophages are also essential in 
controlling swine influenza. Depletion of these cells leads to a lower production of 
TNF and a higher production of IL-10. Macrophage depleted animals also showed 
more severe respiratory signs and higher mortality (Kim et al., 2008). 
The recent outbreak of the “Mexican flu” originally designated “swine flu” virus in 
humans underlines the importance of the pig as a possible source of new influenza 
viruses. Moreover, the same cytokines associated with a SIV infection have been 
demonstrated in NLF of influenza inoculated human volunteers (Hayden et al., 1998) 
and humans are susceptible to the same influenza subtypes as pigs. The symptoms and 
pathology of influenza infections in humans and swine show striking similarities 
(Kuiken and Taubenberger, 2008). The pig lung also shows more morphological and 
physiological resemblances, such as lung size and functional capacity, with human 
lungs than mouse lungs (O'Brien and Zachary, 1996). These pathophysiological 
resemblances between influenza in pigs and humans point out that the pig is a very 
useful experimental animal model to study the pathogenesis of influenza viruses. 
Similarities between pigs and humans in influenza pathology are listed in Table 3. 
 
Table 3. Comparison of human (Hayden et al., 1998; Nicholson, 1998; Kuiken and 
Taubenberger, 2008) and swine (Van Reeth et al., 1999; Olsen et al., 2006) influenza. 
characteristic swine humans 
influenza subtypes H1N1, H3N2, H1N2 H1N1, H3N2, H1N2 
target organs upper and lower RT(1) upper and lower RT 
target cells epithelial cells of RT epithelial cells of RT 
symptoms abdominal thumping, dyspnoe, fever 
sore throat, myalgia, 
chills, fever 
most prominent 
proinflammatory cytokines IFN-α, IL-6 IFN-α, IL-6 
mortality <1% at farm level 0,5% – 1% 
histopathology 
neutrophil infiltration, 
epithelial cell 
desquamation 
necrosis of alveolar epi-
thelium and desquama-
tion, edema fluid 
virus clearance <1 week <1 week 
(1) respiratory tract 
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Aims of the thesis 
 
Swine influenza is an important respiratory disease of pigs with clinical and 
immunological resemblances to influenza in humans. Cytokines probably play a role 
in the development of disease symptoms because strong correlations exist between 
different cytokines (IFN-α and IL-6) and disease symptoms. Currently, diagnosis of 
swine influenza necessitates expensive or technically complicated techniques such as 
virus isolation or hemagglutination inhibition tests. There is a big interest in the use of 
less complicated tests such as ELISAs for the serological diagnosis of swine 
influenza. 
The first aim of the thesis was to examine whether there are alternatives for the 
serological diagnosis of swine influenza. Several ELISA kits for the detection of 
antibodies against swine influenza are commercially available in Europe. They are 
often based on American virus strains and are not yet validated for the detection of 
antibodies against the swine influenza virus strains circulating in Europe. The 
sensitivity and specificity of easily performable commercially available ELISAs were 
compared with the currently used but labour intensive hemagglutination inhibition 
test. Therefore, sera of pigs experimentally inoculated with different European swine 
influenza virus subtypes and animals vaccinated with vaccines against swine 
influenza were evaluated in both tests. 
Secondly, we aimed to describe in more detail the course of different cytokines and 
a few selected acute phase proteins in swine influenza inoculated animals. Until now, 
the role of specific cytokines in the pathogenesis could not be investigated because of 
the lack of cytokine neutralizing antibodies. The second aim of the thesis comprised 
to investigate specifically the role of IFN-α in the pathogenesis of swine influenza by 
using swine IFN-α neutralizing monoclonal antibodies in swine influenza virus 
inoculated gnotobiotic piglets. 
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Abstract. 
 
The IDEXX Swine Influenza Virus H1N1 and H3N2 ELISAs are used worldwide, 
but their capacity to detect antibodies to European swine influenza viruses (SIVs) has 
not been documented. A total of 313 well-defined sera from SIV seronegative pigs 
and pigs experimentally infected with European SIVs were used to compare the 
performance of both ELISAs and the hemagglutination inhibition (HI) test. The 
ELISAs largely failed to detect pigs that had been infected with H1N1 (0/42 positive 
in H1N1 ELISA) or H3N2 only (9/18 positive in H3N2 ELISA; group 1). Higher 
ELISA detection rates were found after consecutive infection of pigs with either 
H1N1 or H3N2 and one other subtype (7/40 and 11/22 positive in H1N1 and H3N2 
ELISA, respectively; group 2). Of 39 pigs that had been vaccinated twice with one of 
4 commercial SIV vaccines (group 3), 25 tested positive in the H1N1 and 4 in the 
H3N2 ELISA. Pigs that had received a single vaccination after a prior infection with 
H1N1 and/or H3N2 (group 4) were more frequently positive than group 1 or 3 pigs 
(23/24 and 15/24 positive in H1N1 and H3N2 ELISA, respectively). Both the H1N1 
and H3N2 ELISA showed a low sensitivity (39% and 35%, respectively) relative to 
the HI test. Because pigs in the field are frequently infected and/or vaccinated with 
multiple SIV subtypes and variants, they are more likely to test positive in the 
ELISAs. However, the interpretation of ELISA results will be difficult and HI 
remains the method of choice. 
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Introduction 
 
“Avian-like” H1N1 and “human-like” H3N2 swine influenza viruses (SIVs) have 
been enzootic in the European swine population since the 1980s, and an H1N2 
reassortant became widespread in the late 1990s. The hemagglutinin (HA) of most 
H1N2 viruses shows little antigenic and genetic relationship with that of the swine 
H1N1 viruses, and it has likely been derived from human H1N1 viruses circulating in 
the 1980s. Still, novel H1N2 reassortants with an avian-like HA have also been 
reported (Pensaert et al., 1981; Marozin et al., 2002). Genetic analyses have further 
shown that all 3 SIV subtypes share similar “avian-like” internal genes. All 3 SIV 
subtypes are widespread in swine-dense regions of Europe, and pigs frequently 
experience consecutive infections with two or even three different SIV subtypes (Van 
Reeth et al., 2008). To further complicate matters, part of the swine population is 
vaccinated against SIV. The SIV vaccines currently commercialized in Europe are 
inactivated, bivalent vaccines. These vaccines contain various H1N1 and H3N2 
influenza strains, some of which are antigenically rather different from the current 
SIV field strains (Van Reeth et al., 2001a). A trivalent vaccine containing H1N1, 
H3N2 and H1N2 strains has been recently developed but is not yet registered. The 
vaccines are used mainly in gilts and sows, which may have been infected with one or 
more SIV subtypes before the first vaccination or at later time points. 
Serologic testing is used for the diagnosis of SIV, to monitor a herd’s immune 
status, to optimize vaccination schedules and for seroprevalence studies. The 
hemagglutination inhibition (HI) test is most frequently used for SIV serology and 
remains the “gold standard”. The test is highly specific and antibody titres correlate 
with protection. However, it also yields variable results dependent on the test virus 
strain and is very labour intensive. Commercial ELISAs for the detection of SIV 
antibodies have recently become available and they can test 46 samples per 96-well 
microtitre plate in just a few hours. All necessary reagents are provided with the kit 
and part of the test can be automated. The IDEXX Swine Influenza Virus H1N1 and 
H3N2 ELISA were developed in North America and appear to be suitable for 
detection of antibodies in pigs exposed to North American H1N1 and H3N2 strains. 
The H1N1 ELISA has shown an excellent specificity and sensitivity in studies with 
sera from pigs vaccinated with SIV vaccines used in the U.S. (Carman et al., 2001; 
Erickson et al., 2002). On the other hand, the ELISA was less sensitive than the HI 
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test in experimental infection studies with U.S. H1N1 viruses (Skibbe et al., 2004; 
Yoon et al., 2004). The H3N2 ELISA was capable of detecting antibodies in pigs 
vaccinated with an experimental U.S. H3N2 SIV-derived modified live vaccine, but 
there is little data on its sensitivity and specificity (Richt et al., 2006). Both tests are 
also used in veterinary diagnostic labs in Europe and for seroprevalence studies 
worldwide (Jung et al., 2002; Vengust et al., 2006; Yoon et al., 2006; Böttcher et al., 
2007; Poljak et al., 2008). The H1N1 and H3N2 SIV field and vaccine strains in 
Europe, however, are antigenically and genetically very different from their 
counterparts in the U.S. (Olsen et al., 2006) and there are concerns about the 
sensitivity of the ELISAs for the detection of antibodies to European SIVs (Lang et 
al., 2007). Still, there are no extensive validation studies with sera to European SIVs. 
This study aimed to assess the capacity of the IDEXX H1N1 and H3N2 ELISAs to 
identify pigs infected with European H1N1 or H3N2 SIV or pigs vaccinated with 
European SIV vaccines. Well-defined sera from previous experimental studies were 
tested in the ELISAs, as well as in HI tests to European H1N1 and H3N2 SIVs. 
Because various and complex situations may occur in the field the study included sera 
from pigs that had been exposed to a) a single SIV infection, b) consecutive infections 
with two SIV subtypes, c) a double vaccination with commercial SIV vaccines and d) 
infection followed by a single vaccination. 
The serum samples used in this study originated from other published and 
unpublished studies (Van Reeth et al., 2001a; Van Reeth et al., 2001b; Van Reeth et 
al., 2006). A total of 313 sera from 106 pigs were examined. The pigs belonged to one 
of 4 experimental groups that are described below. Tables 1&4, 2&5 and 3&6 show 
the different subgroups, the number of pigs in each subgroup and the times of blood 
collection for groups 1&2, 3 and 4, respectively. 
 
Materials and methods 
 
Serum samples 
Group 1: Single inoculation with H1N1, H3N2 or H1N2 SIV. Three groups of pigs 
had been inoculated intranasally with 107.0 EID50 of sw/Belgium/1/98 (H1N1), 
sw/Flanders/1/98 (H3N2) or sw/Gent/7625/99 (H1N2). The virus isolates are 
representative of H1N1, H3N2 and H1N2 viruses currently circulating in the 
European swine population and they are described in detail elsewhere (Van Reeth et 
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al., 2004). After inoculation, infection was confirmed by virus isolation from nasal 
swabs. Blood was collected 0, 2, 4, 6 and 8 weeks after virus inoculation. 
Group 2: Dual, consecutive inoculations with two SIV subtypes. Four groups of 
pigs had been inoculated consecutively with two SIV subtypes at a 4-week interval. 
The subtype combinations included H1N1 followed by H3N2 and vice versa, and 
H1N1 followed by H1N2 and vice versa. The mode and dose of virus inoculation and 
the virus isolates were identical to those in group 1 pigs. Infection with both subtypes 
was confirmed by virus isolation from nasal swabs. Blood was collected 0, 2, 4, 6 and 
8 weeks after the first SIV inoculation. 
Group 3: Vaccination with commercial SIV vaccines. Three groups of 10 pigs each 
had been vaccinated twice intramuscularly with an interval of 3 weeks with one of 3 
commercial SIV vaccines. The following commercial vaccines were used, the 
influenza virus strains in each vaccine are given between brackets: Gripovac® 
(A/New Jersey/8/76 (H1N1) and A/Port Chalmers/1/73 (H3N2); Merial, Lyon, 
France), Suvaxyn Flu® (sw/Netherlands/25/80 (H1N1) and A/Port Chalmers/1/73 
(H3N2); Fort Dodge Animal Health, Madison, New Jersey, USA) and Respiporc 
Flu® (sw/Belgium/230/92 (H1N1) and sw/Belgium/220/92 (H3N2); Impstoffwerk 
Dessau-Tornau Biologika GmbH, Dessau-Roßlau, Germany). Another group of 9 pigs 
had been vaccinated with a trivalent SIV vaccine that is not yet registered. This 
vaccine contains sw/Haselunne/2617/03 (H1N1), sw/Bakum/1769/03 (H3N2) and 
sw/Bakum/1832/00 (H1N2) and is referred to as “trivalent vaccine” (Impstoffwerk 
Dessau-Tornau Biologika GmbH, Dessau-Roßlau, Germany). One group of 10 pigs 
was left unvaccinated. Blood was collected at the time of the first vaccination, and 3 
to 4 weeks after the second vaccination. 
Group 4: Inoculation with H1N1 and/or H3N2 SIV followed by a single 
vaccination with commercial SIV vaccine. Three groups of pigs had been inoculated 
intranasally with H1N1 SIV (sw/Belgium/1/98), with H3N2 SIV (sw/Flanders/1/98) 
or with H1N1 followed 4 weeks later by H3N2. Four to 5 weeks after the last 
inoculation, they were given a single intramuscular vaccination with Gripovac®. One 
control group was left uninoculated and received a single administration of 
Gripovac® only. 
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Enzyme-linked immunosorbent assay 
The IDEXX Swine Influenza Virus H1N1 and H3N2 ELISAs (IDEXX 
Laboratories Inc., Westbrook, Maine, USA) were used according to the 
manufacturer’s instructions. The serum samples were diluted 1/40 in sample diluent 
and 100 µl of positive and negative controls as well as diluted samples were added in 
duplicate to the wells. Thereafter, plates were incubated for 30 min. After removing 
the samples, plates were washed thoroughly and 100 µl of an anti-porcine horseradish 
labelled conjugate was added to all wells. Plates were again incubated for 30 minutes. 
Next, substrate (tetramethylbenzidine) was added after a washing step and fifteen 
minutes later the reaction was stopped with a sodium dodecyl sulphate solution. Next, 
optical densities (OD) were read at 650 nm in an ELISA plate reader. Results were 
expressed as a sample to positive (S/P) ratio by using the following formula: (mean 
sample OD – mean negative control OD)/(mean positive control OD – mean negative 
control OD). Samples with S/P ratios ≥0.4 were considered to be positive for SIV 
antibodies. For the H3N2 ELISA, S/P ratios <0.4 but ≥0.3 were classified as suspect. 
All other S/P ratios were classified as negative. All samples and controls were tested 
in duplicate and the test was performed at room temperature. Arithmetic mean S/P 
ratios of positive samples were calculated. 
 
Hemagglutination inhibition test 
All serum samples were also tested in the HI test using the same H1N1 and H3N2 
strains that were used to inoculate the pigs, namely sw/Belgium/1/98 (H1N1) and 
sw/Flanders/1/98 (H3N2). Serum samples from group 3 animals were also tested for 
HI antibodies against H1N1 and H3N2 vaccine strains. The HI test was performed 
according to standard procedures. Briefly, sera were pre-treated with receptor 
destroying enzyme from Vibrio cholerae (Sigma, St. Louis, Missouri, USA) to 
remove non-specific inhibitors of the agglutination and with a 50% chicken red blood 
cell (RBC) suspension to remove non-specific agglutinins. Serial two-fold dilutions 
(starting at 1:10 dilution) of the pre-treated sera were made in phosphate-buffered 
saline (PBS). After addition of 4 hemagglutinating units of the respective viruses and 
one hour of incubation, a 0.5% chicken RBC suspension was added. One hour later, 
HI titres were recorded as the reciprocal of the last sample dilution that completely 
inhibited hemagglutination. Geometric mean titres of positive samples were 
calculated. 
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Statistical analysis 
Standard two-sample Mann-Whitney tests were used to compare ELISA S/P ratios 
between groups. P <0.05 was taken as the level of significance. Cohen’s Kappa 
coefficient was used to calculate agreement between HI test and ELISA. 
 
Results 
 
Performance of the H1N1 ELISA 
The results of ELISA and HI tests for H1N1 SIV with sera collected after 
infection, vaccination or combinations of both are shown in Tables 1, 2 and 3, 
respectively. 
Groups 1 and 2: Inoculation with one or two SIV subtypes (Table 1). All sera 
collected before SIV inoculation and all but one serum collected after inoculation with 
subtypes other than H1N1 were negative for H1N1 antibodies in the HI test, whereas 
all sera collected after H1N1 inoculation were positive. Individual HI antibody titres 
were between 20 and 160 in the pigs inoculated with H1N1 only or with H1N1 
followed by H3N2. Higher antibody titres (80–320) were seen after H1N1 inoculation 
of previously H1N2 inoculated pigs or vice versa. 
All sera collected before inoculation or after inoculation with H3N2 or H1N2 were 
negative in the ELISA. The sera collected after inoculation with H1N1 only (20 sera 
in group 1 + 22 sera in group 2) were also negative. With one exception, all H1N1-
immune pigs remained negative after subsequent inoculation with H1N2 or H3N2. 
The pigs inoculated with H3N2 followed by H1N1 also tested negative. In the group 
inoculated consecutively with H1N2 and H1N1, all 4 pigs were positive at 2 weeks 
post inoculation with H1N1 and 1 pig was still positive at 4 weeks. Individual S/P 
ratios of positive pigs were between 0.43 and 0.65. All sera that were positive in the 
ELISA had HI antibody titres ≥160, though 13 of the total 20 sera with HI titres ≥160 
were still negative in the ELISA. 
Group 3: Vaccination with commercial SIV vaccines (Table 2). The HI test was 
negative for all sera collected before vaccination or from unvaccinated pigs. All sera 
collected 3–4 weeks after vaccination were positive in the HI test against the 
homologous H1N1 virus and against sw/Belgium/1/98 (Table 2). HI antibody titres to 
the homologous H1N1 vaccine strains were higher than those to sw/Belgium/1/98. 
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     The ELISA was negative for all pre-vaccination sera and for sera from 
unvaccinated controls. Post vaccination sera tested positive for all pigs vaccinated 
with Gripovac® or Suvaxyn Flu®, for 5 out of 10 pigs vaccinated with Respiporc 
Flu® and for none of the pigs vaccinated with the trivalent vaccine. S/P ratios ranged 
between 0.49 and 1.18 and were highest in the pigs vaccinated with Gripovac®  
(P <0.05). 
 
Table 2. Detection of H1N1 antibodies by commercial H1N1 SIV ELISA and HI test 
after a double vaccination of pigs with commercial SIV vaccines (group 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) mean S/P ratio (ELISA) or antibody titre (HI) of the positives only, (2) at the time 
of first vaccination, (3) 3 to 4 weeks after second vaccination, (4) HI titre against 
homologous virus, (5) HI titre against swine/Belgium/1/98, (6) not applicable 
 
Group 4: Inoculation with H1N1 and/or H3N2 SIV followed by a single 
vaccination with commercial SIV vaccine (Table 3). In the HI test, influenza naive 
control pigs and pigs previously infected with H3N2 tested negative for H1N1 
antibodies before vaccination. A single vaccination resulted in an antibody response 
in all control pigs and 2 of the 4 H3N2-immune pigs, but antibody titres to 
sw/Belgium/1/98 remained very low (10–20). All pigs that had been previously 
infected with H1N1 or with H1N1 followed by H3N2 were HI antibody positive 
before vaccination and showed a dramatic booster of H1N1 HI antibodies after a 
single vaccination (320–5120). 
Pre-vaccination sera of the influenza naive control pigs and of the pigs previously 
infected with H3N2 were also negative by ELISA. A single administration of the 
commercial vaccine resulted in an ELISA antibody response in all control pigs and in 
3 out of 4 H3N2-immune pigs. The pigs that had been previously infected with H1N1 
or with H1N1 followed by H3N2 were ELISA antibody negative before vaccination, 
No. of pigs with H1N1 antibodies in: 
ELISA (mean S/P ratio)
(1)
 HI (mean antibody titre)
(1)
 
before vacc.
(2)
 after vacc.
(3)
 
Vaccine n 
before vacc.
(2)
 after vacc.
(3)
 
homol
(4)
 B/1/98
(5)
 homol
(4)
 B/1/98
(5)
 
none 10 0 0 n.a.
(6)
 0 n.a.
(6)
 0 
Gripovac® 10 0 10 (0.98) 0 0 10 (86) 10 (26) 
Suvaxyn Flu® 10 0 10 (0.71) 0 0 10 (80) 10 (30) 
Respiporc Flu® 10 0 5 (0.59) 0 0 10 (171) 10 (57) 
trivalent vaccine 9 0 0 0 0 9 (109) 9 (27) 
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but all of them became positive after a single vaccination. Individual S/P ratios in the 
latter groups were between 0.84–1.44 and between 0.69–1.31, respectively, and they 
were higher than those in the control (0.49–0.86) and H3N2-immune groups (0.39–
0.67) (P <0.05). The positive ELISA S/P ratios after vaccination of the H1N1 immune 
pigs corresponded to high HI antibody titres (320–5120). However, pigs in the control 
and H3N2-immune groups generally had HI antibody titres ≤20 after the vaccination 
and they were also ELISA positive. 
 
Table 3. Detection of H1N1 antibodies by commercial H1N1 SIV ELISA and HI test 
after a single vaccination(1) of pigs with infection-immunity to H1N1, H3N2 or both 
subtypes (group 4). 
 
 
 
 
 
 
 
 
 
 
(1) the commercial vaccine Gripovac® was used for vaccination, (2) mean S/P ratio 
(ELISA) or antibody titre (HI) of the positives only, (3) weeks in relation to 
vaccination, (4) not available 
 
Comparison between HI test and ELISA (Table 7). The overall relative sensitivity 
and specificity of the H1N1 ELISA was 39% and 99%, respectively. Agreement 
between ELISA and HI was low as illustrated by the Cohen’s Kappa coefficient of 
0.37. In Belgium, the prevalence of SIV H1N1 antibodies in fattening pigs is about 
66.7% (Labarque et al., 2004). This gives a positive predictive value (PPV) of 99% 
and a negative predictive value (NPV) of 45%. 
 
 
Performance of the H3N2 ELISA 
The results of ELISA and HI tests for H3N2 SIV with sera collected after 
infection, vaccination or combinations of both are shown in Tables 4, 5 and 6, 
respectively. 
No. of pigs with H1N1 antibodies in: 
ELISA (mean S/P ratio)
(2)
 HI (mean antibody titre)
(2)
 
Virus inoculation(s) 
prior to vaccination 
n 
0 2 6w
(3)
 0 2 6w
(3)
 
none 10 0 10 (0.70) n.a.
(4)
 0 10 (20) n.a. 
H1N1 4 0 4 (0.98) 4 (1.12) 4 (95) 4 (2560) 4 (1522) 
H3N2 4 0 3 (0.61) n.a. 0 2 (20) n.a. 
H1N1-4w-H3N2 6 0 6 (1.00) 6 (1.00) 6 (40) 6 (1810) 6 (1280) 
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    Groups 1 and 2: Inoculation with one or two SIV subtypes (Table 4). All sera 
collected before inoculation and sera collected after inoculation with subtypes other 
than H3N2 were negative for H3N2 antibodies in the HI test, except for 3 out of 4 
animals inoculated with H1N2 followed by H1N1, which had very low HI antibody 
titres (10 – 20). All sera collected after H3N2 inoculation were positive. Individual HI 
antibody titres were between 80 and 320 in the pigs inoculated with H3N2 only and 
between 20 and 160 in pigs inoculated with H3N2 in combination with H1N1. 
Most preinoculation sera and all sera collected after inoculation with H1N1 or 
H1N2 were negative in the ELISA. Four of the total 33 preinoculation sera, however, 
were clearly positive in the ELISA (range 0.83–1.13). All 4 sera were from the singly 
H3N2-inoculated subgroup in group 1 and S/P ratios decreased after the H3N2 
inoculation. Only one of the five singly H3N2-inoculated pigs in group 2 was positive 
in the ELISA, while 5 out of 5 and 4 out of 5 pigs became positive at, respectively, 2 
and 4 weeks after the subsequent inoculation with H1N1. Only one of the 6 H1N1-
immune pigs became positive after inoculation with H3N2. Individual S/P ratios of 
the positive pigs in group 2 ranged between 0.43 and 1.02. All these sera had an HI 
titre ≥40. 
Group 3: Vaccination with commercial SIV vaccines (Table 5). The HI test was 
negative for all sera collected before vaccination or from unvaccinated controls. All 
sera collected 3–4 weeks after vaccination were positive in the HI test against the 
homologous H3N2 virus and against sw/Flanders/1/98 (Table 5). All vaccinated pigs 
had higher HI antibody titres to the homologous H3N2 vaccine strains than to 
sw/Flanders/1/98. The ELISA was negative on the pre-vaccination sera and on sera 
from unvaccinated controls. Only 1 or 2 out of 10 pigs vaccinated with Gripovac®, 
Suvaxyn Flu® or Respiporc Flu®, and none of the pigs vaccinated with the trivalent 
vaccine, tested positive. Individual S/P ratios were ≤0.60. 
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Table 5. Detection of H3N2 antibodies by commercial H3N2 SIV ELISA and HI test 
after a double vaccination of pigs with commercial SIV vaccines (group 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) mean S/P ratio (ELISA) or antibody titre (HI) of the positives only, (2) at the time 
of first vaccination, (3) 3 to 4 weeks after second vaccination, (4) HI titre against 
homologous virus, (5) HI titre against swine/Flanders/1/98, (6) not applicable 
 
Group 4: Inoculation with H1N1 and/or H3N2 SIV followed by a single 
vaccination with commercial SIV vaccine (Table 6). In the HI test, influenza naive 
control pigs and pigs previously infected with H1N1 only tested negative for H3N2 
antibodies before vaccination. Half of these pigs became positive after a single 
vaccination, but antibody titres to sw/Flanders/1/98 remained low (10–40). All pigs 
that were previously infected with H3N2 or with H1N1 followed by H3N2 were HI 
antibody positive before vaccination and showed a dramatic booster of H3N2 HI 
antibodies after a single vaccination (160–2560). 
Pre-vaccination sera of the influenza naive control pigs and of the pigs previously 
infected with H1N1 or with H1N1 followed by H3N2 were negative by ELISA. A 
single administration of the commercial vaccine resulted in an ELISA antibody 
response in none of the control pigs, only 1 of the H1N1-immune pigs, and 5 out of 6 
(H1N1 + H3N2)-immune pigs. Three of the 4 pigs that had been previously infected 
with H3N2 were ELISA positive before the vaccination and all 4 were positive 
thereafter. All 3 infection-immune groups had similar ELISA S/P ratios after 
vaccination, and individual values ranged from 0.40 to 0.91. Except for the serum of 
the H1N1-infection immune pig, all positive sera had HI antibody titres ranging 
between 80 and 2560. 
 
No. of pigs with H3N2 antibodies in: 
ELISA (mean S/P ratio)
(1)
 HI (mean antibody titre)
 (1)
 
before vacc.
(2)
 after vacc.
(3)
 
Vaccine n 
before vacc.
(2)
 after vacc.
(3)
 
homol
(4)
 Fl/1/98
(5)
 homol
(4)
 Fl/1/98
(5)
 
none 10 0 0 n.a.
(6)
 0 n.a.
(6)
 0 
Gripovac® 10 0 1 (0.57) 0 0 10 (92) 10 (26) 
Suvaxyn Flu® 10 0 1 (0.51) 0 0 10 (113) 10 (43) 
Respiporc Flu® 10 0 2 (0.53) 0 0 10 (160) 10 (80) 
trivalent vaccine 9 0 0 0 0 9 (74) 9 (32) 
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Table 6. Detection of H3N2 antibodies by commercial H3N2 SIV ELISA and HI test 
after a single vaccination(1) of pigs with infection-immunity to H1N1, H3N2 or both 
subtypes (group 4). 
 
 
 
 
 
 
 
 
 
 
(1) the commercial vaccine Gripovac® was used for vaccination, (2) mean S/P ratio 
(ELISA) or antibody titre (HI) of the positives only, (3) weeks in relation to 
vaccination, (4) not available 
 
Comparison between HI test and ELISA (Table 7). The overall relative sensitivity 
and specificity of the H3N2 ELISA was 35% and 97%, respectively. Agreement 
between the two tests was low and similar to that of the H1N1 ELISA (Cohen’s 
Kappa coefficient of 0.37). In Belgium, the prevalence of SIV H3N2 antibodies in 
fattening pigs is about 51.2% (Labarque et al., 2004). This gives a PPV of 92% and a 
NPV of 59%. 
 
Table 7. Comparison between HI test and ELISA. 
 
 
 
 
(1) positive predictive value, (2) negative predictive value, (3) agreement expressed as 
Cohen’s Kappa coefficient 
 
Discussion 
 
This is the first extensive validation study of the IDEXX H1N1 and H3N2 SIV 
antibody ELISA with well-defined sera from pigs that had been infected with 
European SIVs or vaccinated with European vaccines. These ELISAs are based on 
North American H1N1 and H3N2 SIVs that are antigenically different from their 
European counterparts. This raises the question as to whether the ELISAs are 
appropriate to detect antibodies against European SIVs and a lack of sensitivity had 
already been reported in a limited European study (Lang et al., 2007). The present 
 Sensitivity Specificity PPV(1) NPV(2) Agreement with HI(3) 
H1N1 ELISA 39% 99% 99% 45% 0.37 
H3N2 ELISA 35% 97% 92% 59% 0.37 
 
No. of pigs with H3N2 antibodies in: 
ELISA (mean S/P ratio)
(2)
 HI (mean antibody titre)
(2)
 
Virus inoculation(s) 
prior to vaccination 
n 
0 2 6w
(3)
 0 2 6w
(3)
 
none 10 0 0 n.a.
(4)
 0 5 (16) n.a. 
H1N1 4 0 1 (0.51) 1 (0.57) 0 0 2 (14) 
H3N2 4 3 (0.61) 4 (0.68) n.a. 4 (135) 4 (640) n.a. 
H1N1-4w-H3N2 6 0 5 (0.65) 4 (0.55) 6 (16) 6 (508) 6 (254) 
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data shows that the ELISAs frequently fail to identify pigs infected with 
contemporary European SIVs or pigs vaccinated with commercial European vaccines, 
especially if they were previously SIV naive. An unexpected specificity problem was 
also encountered with the H3N2 ELISA, in which 4 out of 103 
preinfection/prevaccination sera tested positive. These sera were shown to be negative 
in 3 other serological assays for SIV, including HI and virus neutralization tests and a 
subtype-unrestricted immunoperoxidase monolayer assay, and the nonspecific 
reactions cannot be explained. In contrast with the ELISAs, the HI test showed an 
excellent sensitivity and specificity in the present study. This is in part related to the 
use of identical H1N1 (sw/Belgium/1/98) and H3N2 (sw/Flanders/1/98) strains in the 
test as those used for experimental infection of the pigs. However, these strains are 
still appropriate for the serological diagnosis of the currently circulating SIVs and 
they resemble H1N1 and H3N2 SIVs in other European countries. In addition, all pigs 
vaccinated with commercial SIV vaccines showed HI antibodies to both the 
homologous vaccine viruses and the heterologous strains used in the test. 
Pigs that had been consecutively infected with 2 of the 3 European SIV subtypes 
were more frequently positive in both ELISAs than singly H1N1- or H3N2-infected 
pigs. Similarly, most H1N1 and/or H3N2-infection immune pigs tested positive in the 
ELISAs after a single administration of commercial SIV vaccine. The higher ELISA 
detection rates are likely due to increased antibody levels to the viral HA, as 
demonstrated by the high HI antibody titres in most pigs, or to other viral proteins. 
These observations agree with a study in which only hyperimmune sera, with HI titres 
≥1280 to the homologous virus, were invariably positive in the ELISAs (Schmoll et 
al., 2006). However, the IDEXX H1N1 and H3N2 ELISAs could not discriminate 
between hyperimmune sera to European H1N1, H3N2 or H1N2 strains in that study. 
Also, a second commercial ELISA kit showed a similar low specificity and sensitivity 
as the IDEXX ELISAs. It is noteworthy that in the field, pigs are frequently infected 
and/or vaccinated with multiple influenza virus subtypes and variants. This may 
explain why several field studies report relatively high seropositivity rates in the 
IDEXX ELISAs and, in some cases, a reasonable level of agreement between ELISA 
and HI test results. In one study in the U.S., for example, there was an overall 85.5% 
agreement between the IDEXX H1N1 ELISA and the HI test (Skibbe et al., 2004). In 
a field study in Austria, SIV seroprevalence rates for H1N1 and H3N2 did not differ 
significantly in the IDEXX ELISAs (38% and 15%, respectively) and in the HI test 
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(42% and 19%, respectively) (Lang et al., 2007). The same investigators, however, 
had previously described low sensitivity and specificity of the ELISAs based on 
results with well-defined sera from experimentally infected animals. In addition, more 
than 1/3 of the field sera yielded discrepant results in the IDEXX ELISA and the 
second commercial ELISA kit tested. 
The poor sensitivity of the ELISAs may be due to antigenic differences between 
the strains in the test kits and the European H1N1 and H3N2 SIVs, to a low sensitivity 
of the tests as such, or to a combination of both. Some of the present results suggest 
that antigenic differences may play a role. Only one of the 4 SIV vaccines used 
(Gripovac®) contains a classical H1N1 virus like the IDEXX H1N1 ELISA and pigs 
vaccinated with this vaccine had highest ELISA positivity rates and S/P ratios. On the 
other hand, detailed information is lacking about the strains used in the ELISAs and 
their antigenic relatedness to the SIVs used in the present study, as well as data about 
the protein specificity of the ELISAs. Unlike the HI test, which exclusively detects 
antibodies against the distal, most variable part of the viral HA (Poumbourios et al., 
1993), indirect SIV antibody ELISAs may also detect antibodies against conserved 
viral proteins like matrix proteins or the stem of the HA. More technical details and a 
different experimental set-up are thus needed to determine the reason(s) for the low 
specificity. Interestingly, a low sensitivity of the IDEXX H1N1 ELISA has also been 
reported in two independent experimental infection studies with North American, 
classical H1N1 SIVs from 1992 (Skibbe et al., 2004; Yoon et al., 2004). In these 
studies the ELISA detected antibodies in only 6 of 72 and 35 of 60 post-infection sera 
examined, while all sera were positive in HI tests. The ELISA clearly failed to 
identify H1N1-seropositive animals as effectively as the HI test, especially at the 
early stage of infection. Other investigators have tested pig hyperimmune sera against 
10 antigenically different U.S. H1 SIVs isolated between 1930 and 2004 (Vincent et 
al., 2006). These sera were obtained by a double vaccination of pigs with inactivated 
virus followed by a live virus challenge. All sera showed high HI antibody titres 
(≥640) to the homologous virus, but the ELISA was only marginally above the S/P 
positive cut-off ratio of 0.4 for some modern H1 strains. The authors therefore 
concluded that the HI assay with a panel of H1 and H3 viruses is a better diagnostic 
test for swine influenza than the ELISA. 
SIV serology is more challenging now than in the past. Over the last 10 years 
novel SIV subtypes and reassortants have emerged in both Europe and North 
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America. Besides, the H1N1, H3N2 and H1N2 SIVs on both continents have a 
different genetic constellation and antigenically distinct HA proteins (Olsen et al., 
2006). The value of antibody ELISAs based on whole SIVs is diminished in this 
complex epidemiological situation. In fact, there are currently only 2 options for the 
serological diagnosis of SIV. A first option is to perform HI tests using strains that are 
antigenically similar to the predominant SIVs in a given region. In most regions of 
Western Europe, at least 3 separate HI tests including SIVs with an avian-like H1, a 
human-like H1 and an H3 are required. Though serological cross-reactions can not be 
completely excluded, the HI test can largely discriminate between antibodies to these 
3 HAs in unvaccinated pigs (Van Reeth et al., 2006). A second option is to use one 
subtype-unrestricted universal antibody ELISA based on conserved influenza virus 
proteins (Kim et al., 2006). The nucleoprotein (NP) appears to be the best candidate 
for this purpose (Kim et al., 2006) and several NP-based, usually multi-species 
ELISA kits are on the market. This second approach is less complicated than the HI 
test, but it does not provide information about the subtype or antigenic characteristics 
of the infecting viruses. Caution must be exerted, however, because there is no 
published data about the performance of such commercial influenza antibody ELISAs 
with sera from infected or vaccinated pigs. In preliminary investigations with one of 
these kits and sera from the present study, pigs infected with 1 or with 2 different SIV 
subtypes (groups 1 and 2) were usually positive. Part of the vaccinated pigs (group 3), 
in contrast, tested negative and further validation studies are certainly needed. Finally, 
ELISA tests based on the influenza virus non-structural NS1 protein, which is 
expressed only during viral replication, appear to be suitable to differentiate pigs 
vaccinated with current killed vaccines from infected animals (Kim et al., 2006). Such 
tests are not yet commercially available and they could considerably improve the 
serological diagnosis of SIV. 
In conclusion, the HI test remains the method of choice for the serological 
diagnosis of SIV, to monitor a herd’s immune status or to determine the prevalence of 
specific SIV subtypes in the European swine population. The IDEXX SIV ELISAs 
will likely detect part of the SIV-infected and/or vaccinated pigs under field 
conditions, but the interpretation of positive ELISA test results will be difficult. 
 
Chapter 3 _____________________________________________________________________ 
58 
Acknowledgements 
 
The authors thank Lieve Sys, Melanie Bauwens and Nele Dennequin for technical 
assistance and Fernand De Backer for help with animal experiments. We would also 
like to thank IDEXX Laboratories Inc. for providing the ELISA kits. This study was 
in part supported by the “European Surveillance Network for Influenza in Pigs 2 
(ESNIP2)” (SSPE-CT-2005-022749) and “Lab-on-site” (SSPE-CT-2004-513645), a 
co-ordination action and specific targeted research project, respectively, in the 6th 
framework program of the European Commission. 
 
ELISA for serodiagnosis of swine influenza _____________________________________________________________________ 
59 
References 
 
Böttcher, J., Gangl, A., Alex, M., Niemeyer, H., 2007. Endemic circulation of swine 
influenza virus (SIV) in the absence of disease. In: Proceedings of the 5th International 
Symposium on Emerging and Re-emerging Pig Diseases, Krakow, Poland, p. 255. 
Carman, S., McEwen, B., Josephson, G., 2001. Validation of IDEXX H1N1 swine 
influenza virus ELISA. AHL newsletter 5 (4), 56. 
Erickson, G., Rapp-Gabrielson, V., Jackson, T., Eddy, B., Gergen, L., Bennett, K., 
Velek, K., 2002. Duration of HI and ELISA antibodies following vaccination against 
SIV. In: Proceedings of the 17th IPVS Congress, Ames, Iowa, USA, p. 180. 
Jung, T., Choi, C., Chung, H.K., Kim, J., Cho, W.S., Jung, K., Chae, C., 2002. Herd-
level seroprevalence of swine-influenza virus in Korea. Prev. Vet. Med. 53 (4), 311-
314. 
Kim, W.I., Wu, W.H., Janke, B., Yoon, K.J., 2006. Characterization of the humoral 
immune response of experimentally infected and vaccinated pigs to swine influenza 
viral proteins. Arch. Virol. 151 (1), 23-36. 
Labarque, G., Vyt, P., Van Reeth, K., Pensaert, M., 2004. Seroprevalence of different 
swine influenza virus subtypes in swine in Belgium in 2001-2003. In: Proceedings of 
the 18th IPVS Congress, Hamburg, Germany, p. 84. 
Lang, C., Sipos, W., Dürrwald, R., Herwig, V., Selbitz, H.J., Sommerfeld-Stur, I., 
Schmoll, F., 2007. Hämagglutinationsinhibitionstest und kommerzielle ELISA-Kits 
zum Nachweis von Antikörpern gegen Schweininfluenzavirus Typ A-H1N1 und -
H3N2 differieren in ihrer diagnostischen Aussagekraft [Swine influenza: diagnostic 
significance of the haemagglutination inhibition assay and commercial ELISA-kits]. 
Wien. Tierärztl. Mschr. 94 (11-12), 296-303. 
Marozin, S., Gregory, V., Cameron, K., Bennett, M., Valette, M., Aymard, M., Foni, 
E., Barigazzi, G., Lin, Y., Hay, A., 2002. Antigenic and genetic diversity among 
swine influenza A H1N1 and H1N2 viruses in Europe. J. Gen. Virol. 83735-745. 
Olsen, C.W., Brown, I., Easterday, B.C., Van Reeth, K., 2006. Swine Influenza, In: 
Straw, B.E., Zimmerman, J.J., D'Allaire, S., Taylor, D.J. (Eds.) Diseases of Swine. 
Iowa State University Press, Ames, Iowa, pp. 469-482. 
Pensaert, M., Ottis, K., Vandeputte, J., Kaplan, M.M., Bachmann, P.A., 1981. 
Evidence for the natural transmission of influenza A virus from wild ducks to swine 
and its potential importance for man. Bull. World Health Org. 59 (1), 75-78. 
Poljak, Z., Dewey, C.E., Martin, S.W., Christensen, J., Carman, S., Friendship, 
R.M., 2008. Prevalence of and risk factors for influenza in southern Ontario swine 
herds in 2001 and 2003. Can. J. Vet. Res. 72 (1), 7-17. 
Chapter 4 _____________________________________________________________________ 
60 
Poumbourios, P., Oxford, J.S., Jackson, D.C., 1993. Studies on the antibody-response 
of mice and humans after immunization with potential influenza virus-A (H1N1) 
vaccines. Immunol. Cell Biol. 7113-25. 
Richt, J.A., Lekcharoensuk, P., Lager, K.M., Vincent, A.L., Loiacono, C.M., Janke, 
B.H., Wu, W.H., Yoon, K.J., Webby, R.J., Solorzano, A., Garcia-Sastre, A., 2006. 
Vaccination of pigs against swine influenza viruses by using an NS1-truncated 
modified live-virus vaccine. J. Virol. 80 (22), 11009-11018. 
Schmoll, F., Lang, C., Dürrwald, R., Herwig, V., Laue, C., Sommerfeld-Stur, I., 
Sipos, W., 2006. Restriction of commercial swine influenza ELISA kits for subtype-
specific differentiation of swine influenza A-viruses. In: Proceedings of the 19th IPVS 
congress, Copenhagen, Denmark, p. 135. 
Skibbe, D., Zhou, E.M., Janke, B.H., 2004. Comparison of a commercial enzyme-
linked immunosorbent assay with hemagglutination inhibition assay for serodiagnosis 
of swine influenza virus (H1N1) infection. J. Vet. Diagn. Invest. 16 (1), 86-89. 
Van Reeth, K., Brown, I., Essen, S., Pensaert, M., 2004. Genetic relationships, 
serological cross-reaction and cross-protection between H1N2 and other influenza A 
virus subtypes endemic in European pigs. Virus Res. 103 (1-2), 115-124. 
Van Reeth, K., Brown, I.H., Dürrwald, R., Foni, E., Labarque, G., Lenihan, P., 
Maldonado, J., Markowska-Daniël, I., Pensaert, M., Pospisil, Z., Koch, G., 2008. 
Seroprevalence of H1N1, H3N2 and H1N2 influenza viruses in pigs in seven 
European countries in 2002-2003. Influenza Other Resp. Viruses 2 (3), 99-105. 
Van Reeth, K., De Clercq, S., Pensaert, M., 2001a. The significance of antigenic 
evolution for vaccine efficacy: learning from vaccination-challenge studies in pigs. In: 
Proceedings of the Symposium on Emergence and Control of zoonotic Ortho- and 
Paramyxovirus disease, Paris, France, pp. 99-106. 
Van Reeth, K., Labarque, G., De Clercq, S., Pensaert, M., 2001b. Efficacy of 
vaccination of pigs with different H1N1 swine influenza viruses using a recent 
challenge strain and different parameters of protection. Vaccine 19 (31), 4479-4486. 
Van Reeth, K., Labarque, G., Pensaert, M., 2006. Serological profiles after 
consecutive experimental infections of pigs with European H1N1, H3N2, and H1N2 
swine influenza viruses. Viral Immunol. 19 (3), 373-382. 
Vengust, G., Valencak, Z., Bidovec, A., 2006. A serological survey of selected 
pathogens in wild boar in Slovenia. J. Vet. Med. B Infect. Dis. Vet. Public Health 53 
(1), 24-27. 
Vincent, A.L., Lager, K.M., Ma, W., Lekcharoensuk, P., Gramer, M.R., Loiacono, 
C., Richt, J.A., 2006. Evaluation of hemagglutinin subtype 1 swine influenza viruses 
from the United States. Vet. Microbiol. 118 (3-4), 212-222. 
ELISA for serodiagnosis of swine influenza _____________________________________________________________________ 
61 
Yoon, J.S., Han, J.H., Jeong, H.K., Kim, H.J., 2006. Sero-prevalence of swine 
influenza virus (H3N2) in Korea according to age of pigs and season. In: Proceedings 
of the 19th IPVS congress, Copenhagen, Denmark. 
Yoon, K.J., Janke, B.H., Swalla, R.W., Erickson, G., 2004. Comparison of a 
commercial H1N1 enzyme-linked immunosorbent assay and hemagglutination 
inhibition test in detecting serum antibody against swine influenza viruses. J. Vet. 
Diagn. Invest. 16 (3), 197-201. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
__________________________________________________ 4. 
ROLE OF IFN-α  AND OTHER CYTOKINES IN THE PATHOGENESIS OF SWINE 
INFLUENZA 
 
 
 
 
 
 
 
 
 
 
___________________________________________________ 
  
 
 
 
  
 
 
 
 
 
 
_________________________________________________ 4.1 
CYTOKINES AND ACUTE PHASE PROTEINS DURING THE ACUTE STAGE OF A SWINE 
INFLUENZA VIRUS INFECTION 
 
 
 
 
 
 
 
 
 
 
 
___________________ The Veterinary Journal (2009) conditionally accepted 
 Barbé, F., Atanasova, K., Van Reeth, K. 
 
 
 
Chapter 4 
_____________________________________________________________________ 
66 
Abstract 
 
This study investigated the profile of various (pro)inflammatory cytokines and 
acute phase proteins (APP) during a swine influenza virus (SIV) infection. Three-
week-old caesarean-derived colostrum-deprived (CDCD) piglets were inoculated 
intratracheally with 107.5 EID50 Swine/Belgium/1/98 (H1N1) SIV and sacrificed 
between 0 and 120 hours post inoculation (PI). Broncho-alveolar lavage fluid 
(BALF), lung homogenates and sera were examined for the inflammatory mediators 
by bioassay or ELISA. IFN-α, IL-6, IL-1 and TNF peaked in BALF 24–30h PI, when 
virus titres and symptoms were maximal. IFN-γ and IL-12 but not IL-18 in BALF 
increased simultaneously, and serum cytokine titres were either undetectable or up to 
100-fold lower than those in BALF. The APP C-reactive protein (CRP) and 
haptoglobin peaked 24h later than the cytokines and reached higher levels in serum 
than in BALF, while LPS-binding protein (LBP) rose in BALF only. Lung virus titres 
were tightly correlated with BALF IFN-α, IL-6, IL-1, TNF, IFN-γ and IL-12, as well 
as with serum levels of IL-6 and the interferons. Disease was correlated with the same 
cytokines in BALF and in serum, as well as with BALF LBP and serum CRP. We 
conclude that IFN-γ and IL-12 probably also play a role in SIV pathogenesis and that 
APP present in serum and BALF are cytokine induced. The pig is a valuable model to 
further examine the therapeutic potential of cytokine antagonists in influenza 
infection. 
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Introduction 
 
Swine influenza virus (SIV) is a major cause of acute respiratory disease in swine 
(Loeffen et al., 1999). Typical outbreaks are characterized by high fever, depression, 
anorexia and a laboured abdominal breathing (Shope, 1931; Olsen et al., 2006). SIV 
replicates in epithelial cells of the nasal mucosa, tonsils, trachea and lungs, which 
appear to be the major target organ. Fully susceptible influenza-naive pigs usually 
show extensive gross lung lesions, and microscopic examination of the lungs reveals 
necrosis and desquamation of the bronchiolar epithelial cell layer and infiltration of 
neutrophils (Olsen et al., 2006). The infection is generally limited to the respiratory 
tract and attempts to demonstrate viraemia or virus replication outside the respiratory 
tract have been largely unsuccessful. The disease can be reproduced experimentally 
by intratracheal (IT) inoculation of influenza-naive pigs with a high virus dose (107.5 
EID50). This results in respiratory and general symptoms, high lung titres of virus 
(≥108.0 TCID50/g), several (pro)inflammatory cytokines and >50% of neutrophils in 
broncho-alveolar lavage (BAL) fluid (BALF) cells within 1 day post inoculation (PI). 
Previous experimental infection studies with representative H1N1, H3N2 and H1N2 
SIV strains showed highly significant correlations between clinical signs and levels of 
interferon-α (IFN-α), interleukin-6 (IL-6) and tumour necrosis factor (TNF) in BALF 
(Van Reeth et al., 2002). The correlation between disease and IL-8 or IL-1, on the 
other hand, was much weaker. The typical symptoms and pathology of influenza in 
pigs resemble those in naive humans and the cytokine profile in BALF of pigs is 
similar to that in nasal lavage fluids of experimentally infected human volunteers 
(Hayden et al., 1998). In addition, pigs are naturally susceptible to the same influenza 
A virus subtypes as humans (H1N1, H3N2, H1N2) and show physiological and 
anatomical resemblances to humans. Therefore pigs are a valuable experimental 
model to study the pathogenesis of influenza and the role of cytokines therein (Kuiken 
and Taubenberger, 2008). 
Apart from the cytokines mentioned higher, other cytokines like IL-12, IL-18 and 
IFN-γ may also play a role in influenza pathogenesis. IL-12 is a potent regulator of 
cell-mediated immune responses such as proliferation of and IFN-γ production by T- 
and NK-cells (Gately et al., 1991; Monteiro et al., 1998). IFN-γ has also numerous 
immunological functions such as enhancement of MHC expression, and limited 
antiviral activity. IL-18 is often considered as an “IFN-γ inducing factor” (Konishi et 
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al., 1997). Intranasal inoculation of human volunteers with A/Texas/36/91 (H1N1) 
resulted in an increase in IFN-γ in nasal lavage fluid 2-5 days PI (Fritz et al., 1999). In 
mice inoculated with A/PuertoRico/8/34 (H1N1), both IFN-γ and IL-12 were found in 
BALF 3-7 days PI (Monteiro et al., 1998). Intraperitoneal treatment of mice with anti-
IL-12 antibodies resulted in lower IFN-γ titres but higher lung virus titres (Monteiro 
et al., 1998). A study involving IL-18 knock out mice also pointed towards a role for 
IL-18 in influenza virus clearance from the lungs and in the induction of IFN-γ 
(Denton et al., 2007). In the swine influenza model, IL-12 and IL-18 have never been 
studied and data about IFN-γ are scarce (Jung et al., 2004). 
Acute phase proteins (APP) can also play a role in the pathogenesis of respiratory 
infections. APP such as haptoglobin (HG), lipopolysaccharide (LPS) binding protein 
(LBP) and C-reactive protein (CRP) are produced by the liver in response to 
cytokines (Moshage et al., 1988). HG binds free haemoglobin thus removing it from 
the circulation. LBP binds LPS leading to its neutralization and clearance. CRP has 
several functions such as macrophage activation and opsonisation. IL-6, IL-1 and 
TNF appear to be the main APP inducers (Petersen et al., 2004). A number of studies 
have investigated APP during influenza infections. During experimental influenza 
virus infection of human volunteers CRP in sera peaked at 3 days PI (Whicher et al., 
1985). In people suffering from a natural influenza infection CRP was significantly 
increased in acute sera compared to convalescent sera taken 4-6 weeks later (Falsey et 
al., 2001). Another study showed a similar profile with peak serum CRP levels at 3 
and 4 days PI followed by a decline and very low levels at 2 weeks PI (Melbye et al., 
2004). Increased HG concentrations were found after experimental influenza virus 
infection of horses (Kent and Goodall, 1991), peaking 7-10 days PI. In horses 
naturally infected with equine influenza virus, serum amyloid A was increased in the 
acute stage of the disease (Hulten et al., 1999). To our knowledge APP have not yet 
been studied in influenza-inoculated pigs. 
A more complete picture of the cytokine and APP profile during SIV infection will 
increase our understanding of the pathogenesis of influenza in both pigs and humans. 
The first aim of this study was to investigate the profile of IFN-γ, IL-12 and IL-18 as 
well as of APP (HG, LBP and CRP) during a SIV infection. The second aim was to 
compare levels of these cytokines and APP in the lungs and in the circulation. Finally, 
we have investigated correlations between different cytokines, APP, lung virus titres 
and neutrophil infiltration. 
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Materials and Methods 
 
Virus 
The Swine/Belgium/1/98 (H1N1) SIV strain had been isolated from the lungs of 
fattening pigs during an acute respiratory disease outbreak. The stock used for 
inoculation represented the third passage in eggs. Virus inoculations of pigs were 
performed IT, using 107.5 EID50 in 3 mL phosphate-buffered saline (PBS), by 
inserting a 20-gauge needle attached to a syringe in the trachea through the skin 
cranial to the sternum.  
 
Pigs, experimental design, sampling and BALF cell analysis 
Sixteen 3-week-old caesarean-derived colostrum-deprived (CDCD) pigs were 
used. The pigs originated from 2 sows and were housed in Horsefall-type isolation 
units with positive-pressure ventilation and fed with ultrahigh-temperature-treated 
cow’s milk supplemented with antibiotics. Two pigs were mock-inoculated with PBS 
and euthanized 1 day later. The 14 remaining pigs were inoculated IT with SIV and 
euthanized at 24 h (n=3), 30 h (n=2), 48 h (n=3), 72 h (n=3) or 120 h (n=3) PI. 
Euthanasia was performed intravenously by injecting an overdose sodium 
pentobarbital (Natrium Pentobarbital 20%, Kela). A clinical score to assess disease 
was attributed to each pig just before euthanasia whereby one point was assigned for 
the presence of each of following signs: anorexia, depression and coughing. A 
respiration frequency from 60 - 90 respirations per minute added 1 point, and > 90 
respirations per minute added 2 points to the clinical score. The Local Ethical 
Committee of the Faculty of Veterinary Medicine, Ghent University approved this 
experiment (authorisation reference number EC 2005/88). 
Blood samples for serum collection were taken from all pigs at euthanasia. The whole 
lung was excised and the right lung half was lavaged with cold PBS to obtain BALF 
as described elsewhere (Van Reeth et al., 1999). Samples from the left lung lobes 
were pooled and 20% tissue homogenates were prepared for virus titration and 
quantification of cytokines. BALF was separated into cells and cell-free fluids by 
centrifugation. Cell-free BALF was concentrated 20 times by dialysis against 
polyethylene glycol, cleared of residual virus by centrifugation and used to determine 
cytokines and APP as described further. 
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BALF cell analysis 
Total numbers of BALF cells were counted using a Türk chamber. Cytocentrifuge 
preparations were stained with Diff-Quik® (Medion Diagnostics) to determine 
neutrophil numbers. 
 
Virological examination 
Virus titrations of lung homogenates were performed in Madin-Darby Canine 
Kidney cells as described previously (Van Reeth et al., 2002). Virus titres were 
calculated using the method of Reed and Muench (Reed and Muench, 1938). 
 
Quantification of cytokines 
Sera, BALF and lung tissue homogenates were used for quantification of various 
cytokines. IFN-α, TNF, IL-1 and IL-6 were assayed using bioassays as described 
earlier (Van Reeth et al., 1999; Van Reeth et al., 2002). In summary, IFN-α was 
quantified in a cytopathic effect reduction test with Madin-Darby Bovine Kidney cells 
and vesicular stomatitis virus. TNF titres were determined in a cytotoxicity test in 
Porcine Kidney subclone 15 (PK(15)) cells and IL-1 activity was measured in a 
proliferation assay in D10(N4)M cells. IL-6 was assayed in a proliferation assay using 
B9 cells. All bioassays were run two or three times and geometric mean titres were 
calculated. Specificity was demonstrated by neutralizing the samples with specific 
antibodies for IFN-α, TNF and IL-6 or pre-incubation of the D10(N4)M cells with IL-
1 receptor antagonist. IFN-γ, IL-18 and IL-12 were determined by ELISAs (Swine 
IFN-γ ELISA (Biosource), Pig IL-18 ELISA (BenderMed Systems), Porcine IL-
12/IL-23 p40 ELISA (R&D Systems)). Detection limits of these tests were 2, 23 and 
18 pg/mL, respectively. All samples were tested in duplicate and ELISAs were 
performed as instructed by the manufacturers. 
 
Quantification of APP 
CRP, HG and LBP were measured in serum and BALF. CRP and LBP were 
quantified by ELISAs (Phase Range Porcine C-reactive Protein Assay, Tridelta 
Development Ltd. and LBP ELISA, Hycult Biotechnology). HG was measured using 
a colorimetric assay (Phase Range Porcine Haptoglobin Assay, Tridelta Development 
Ltd.). Detection limits of CRP, LBP and HG were 47 ng/mL, 1,6 ng/mL and 50 
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µg/mL, respectively. All samples were tested in duplicate according to manufacturers’ 
instructions. 
 
Statistical evaluation 
Spearman rank correlation coefficients (ρ) were calculated to compare individual 
cytokine and APP levels in the lungs or circulation, lung virus titres, neutrophil 
numbers in BALF and clinical scores. P < 0.01 was taken as the level of significance. 
 
Results 
 
Clinical symptoms, virus titres and lung inflammatory changes 
The PBS-inoculated control pigs did not show symptoms, were free of virus in 
their lungs and had negligible numbers of neutrophils (1 x 106) in BALF. In the SIV 
inoculated pigs, clinical signs consisted of abdominal thumping, tachypnoea and 
depression. These symptoms peaked at 24 and 30 h PI and had completely resolved 
by 72 h PI (Table 1). Lung virus titres were maximal at 24 and 30 h PI (109.6 
TCID50/g) and showed a substantial decrease at 4 and 5 days PI (105.8 TCID50/g). 
BALF cell numbers were strongly increased at 24 and 30 h PI (peak of 828 x 106). 
Increased BALF cell numbers were largely due to neutrophil infiltration since the 
number of monomorphonuclear cells remained rather constant (± 120 x 106) during 
the experiment (Table 1). Neutrophil numbers had dropped substantially by 3 and 5 
days PI (8-20 x 106), approaching baseline levels. 
 
Profile of cytokines in BALF, serum and lung tissue suspensions 
Titres of bioactive IFN-α, IL-6, TNF and IL-1 in BALF, lung tissue suspensions 
and serum are shown in Figures 1A, 1B and 1C. The profile of IFN-α, TNF, IL-1 and 
IL-6 in BALF was in agreement with that in previous studies (Van Reeth et al., 1999; 
Van Reeth et al., 2002). All 4 cytokines were undetectable in all 3 compartments 
(BALF, serum and lung tissue suspensions) in PBS-inoculated pigs and were strongly 
increased in BALF 24 and 30 h PI with SIV. At later time points they were at least 
20-fold lower or near the detection limit. Titres of IFN-α and IL-6 were about 100 
times higher than TNF and IL-1 titres (see insert Fig. 1A). In lung tissue homogenates 
(Fig. 1B) and serum (Fig. 1C) the cytokine profiles were similar but cytokine titres 
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were, respectively, about 10 and 100 times lower than in BALF. Only IFN-α and IL-6 
were substantially increased in lung tissue homogenates and serum. 
 
Table 1. Evolution of mean clinical score at euthanasia, lung virus titres and 
inflammatory changes in the lungs after intratracheal inoculation of pigs with swine 
influenza virus. 
Cell numbers in BALF (1) (x106) ± SD 
h PI n 
Clinical 
score ± SD 
Virus titre ± SD 
(log10 TCID50/g) Total Neutrophil Mononuclear 
0 2 0.0 ± 0.0 <1.7 ± 0 131 ± 18 1 ± 0 130 ± 18 
24 3 1.7 ± 1.5 9.6 ± 0.3 458 ± 310 332 ± 336 126 ± 50 
30 2 3.5 ± 0.7 9.2 ± 0.2 614 ± 303 481 ± 211 133 ± 92 
48 3 1.7 ± 1.2 8.7 ± 0.3 331 ± 131 114 ± 113 217 ± 122 
72 3 0.0 ± 0.0 7.5 ± 0.7 118 ± 24 11 ± 3 107 ± 26 
120 3 0.0 ± 0.0 5.8 ± 0.6 228 ± 18 15 ± 5 213 ± 20 
(1) broncho-alveolar lavage fluid 
 
 
Titres of IL-12, IFN-γ and IL-18 in BALF, lung tissue suspensions and serum are 
shown in Figures 2A, 2B and 2C. In the mock-inoculated pigs, only IL-18 was 
detectable, in all 3 compartments. In BALF, IL-12 and IFN-γ peaked at 24 and 30 h 
PI and gradually declined thereafter. IL-18 levels, in contrast, were lower at 24 and 30 
h PI than at 0 h PI and they increased thereafter. Lung tissue suspensions revealed a 
similar cytokine profile as BALF, but IFN-γ and IL-18 levels were, respectively, 
about 2 and 10 times higher. In serum, IL-12 was absent at all time points, and IFN-γ 
and IL-18 concentrations were, respectively, about 10 and 2 times lower than in 
BALF. IL-18 dropped below the detection limit in serum at 30 h PI, along with the 
decrease of IL-18 in the other two compartments. 
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Figure 1. Evolution of IFN-α (), IL-6 (), TNF () and IL-1 () in BALF (A), 
lung tissue homogenates (B) and serum (C) during a swine influenza virus infection. 
Values are means of 2 or 3 pigs (+ standard error of mean; SEM), and are expressed 
as biological units/mL (BALF and serum) or per gram (lung tissue homogenates). 
 
Profile of APP in BALF and serum 
Levels of LBP, HG and CRP were only examined in BALF and serum (Fig. 3A 
and 3B). The PBS-inoculated control pigs had low HG and LBP levels in BALF and 
undetectable CRP. Sera of PBS-inoculated control pigs showed undetectable or low 
levels of CRP and HG, but substantial levels of LBP. In SIV-inoculated pigs, 
concentrations of APP in BALF peaked at 30 h PI (LBP) or 48 h PI (HG and CRP) 
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and decreased thereafter. In serum, CRP and HG showed a peak at 48 h PI, while LBP 
did not change much. APP levels in serum were roughly 4 times higher than in BALF. 
 
 
Figure 2. Evolution of IL-12 (), IFN-γ () and IL-18 () in BALF (A), lung tissue 
homogenates (B) and serum (C) during a swine influenza virus infection. Values are 
means of 2 or 3 pigs (+ SEM), and are expressed as pg/mL (BALF and serum) or pg/g 
(lung tissue homogenates). 
 
Cytokines and acute phase proteins in swine influenza 
_____________________________________________________________________ 
75 
 
Figure 3. Evolution of HG (), LBP () and CRP () in BALF (A) and serum (B) 
during a swine influenza virus infection. Values are means of 2 or 3 pigs (+ SEM), 
and are expressed in µg/mL (HG) or ng/mL (LBP and CRP). 
 
 
Correlations between parameters 
Correlations between lung virus titres, neutrophil infiltration in BALF and clinical 
scores on the one hand and cytokines and APP in BALF or serum on the other hand 
are described in Table 2 and 3, respectively. Virus titres and neutrophil percentages in 
BALF were significantly correlated with each other and also with all cytokines in 
BALF, except for IL-18. Disease, assessed by clinical scores, correlated significantly 
with lung virus titres, neutrophil infiltration and all cytokines in BALF although there 
was a negative correlation with IL-18. Of the APP in BALF only LBP correlated with 
disease. The strongest correlations were found between virus titres and IFN-α (ρ = 
0.962) or IL-6 (ρ = 0.940). Cytokines in BALF (except IL-18) were also significantly 
correlated with each other with a Spearman rank correlation coefficient (ρ) of at least  
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0.717. IL-18 was negatively but not significantly correlated with all parameters 
examined. Of the APP, only LBP correlated significantly with other parameters, 
namely IL-6, IL-12 and neutrophil infiltration. 
In serum, IL-1, TNF and IL-12 were below the detection limit and correlation 
coefficients for these cytokines could not be calculated. As for BALF, there were 
strong correlations between lung virus titres, neutrophil infiltration or disease on the 
one hand and IFN-α, IFN-γ and IL-6 on the other hand and between those cytokines 
(ρ ≥ 0.770). IL-18 was negatively but not significantly correlated with other 
parameters. The only significant correlation for APP in serum was between HG and 
CRP and between CRP and disease. 
Correlations between cytokines in BALF and APP in serum were also calculated 
(data not shown). The only significant, but negative, correlation existed between  
IL-18 in BALF and CRP in serum (ρ = -0.681). 
 
Discussion 
 
The present study confirms and adds to our previous studies on the cytokine profile 
in BALF during experimental SIV infection. Those previous studies showed 
significant increases in IFN-α, TNF, IL-6 and IL-1, and the first three cytokines in 
particular were strongly correlated with virus replication and disease (Van Reeth et 
al., 2002). The present study demonstrates a similar secretion profile and correlations 
for IL-12 and IFN-γ, but not for IL-18. We also found increases in the APP HG, LBP 
and CRP but, unlike for the cytokines, their levels were higher in serum than in BALF 
and they peaked 24 h later than the cytokines. In addition, APP were not directly 
correlated with virus replication and correlations with disease were rarely significant. 
IFN-γ was detected in both BALF and serum 24 h PI with SIV. This finding 
contrasts with two other studies on IFN-γ during experimental SIV infection. 
Infection with a Korean H1N1 SIV resulted in a small and non-significant increase in 
ELISA IFN-γ titres in BALF, at 7 days PI only (Jung et al., 2004). Similarly, serum 
ELISA titres of IFN-γ did not change after infection with a US H3N2 SIV isolate 
(Wesley et al., 2006). Several factors may account for the higher and more rapid  
IFN-γ response in our study. We used a higher virus inoculation dose than in both 
other studies, and intratracheal instead of intranasal inoculation, which results in a 
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higher virus load in the lungs. Unlike Jung et al. (2004), we used concentrated BALF, 
which increases the sensitivity of cytokine detection, and we focused on earlier times 
PI than in both other studies. Furthermore, the profiles of IFN-γ and IL-12 in BALF in 
our pig model of influenza largely agreed with those in BALF of BALB/c mice and 
nasal lavage fluid of human volunteers, respectively (Monteiro et al., 1998; Fritz et 
al., 1999). 
IL-18 was unexpectedly present in BALF, lung homogenates and serum of PBS-
inoculated controls and decreased after SIV inoculation. Both findings are difficult to 
explain. It is known that IL-18 is expressed intracellularly as a precursor form and 
that IL-1β converting enzyme (ICE) cleaves the intracellular pro-IL-18 protein into 
mature IL-18 which is then released from the cell (Ghayur et al., 1997). The 
commercial ELISA used in our study will most likely detect the extracellular, mature 
form of IL-18, though the manufacturer could not provide any information on this 
issue. IL-18 seems to be constitutively expressed in rats and humans. In one study in 
rats, high ELISA levels of IL-18 were found in lung homogenates (Jordan et al., 
2001) and pro- and mature IL-18 was detected in freshly isolated human peripheral 
blood mononuclear cells (PBMC) (Puren et al., 1999). IL-18 levels around 700 pg/mL 
were also found in BALF of uninfected one-day-old gnotobiotic pigs using a non-
commercial ELISA. BALF IL-18 levels in these piglets, however, were significantly 
increased at 2 and 4 weeks PI with Mycoplasma hyopneumoniae (Muneta et al., 
2008). A transient increase in IL-18 ELISA concentrations was also observed in 
BALF of other animal species following experimental infection with various 
pathogens. This was the case, for example, at 3 days PI of mice with herpes simplex 
virus type 1 (HSV-1), while IL-18 was undetectable at 1 or 7 days PI or in 
uninoculated controls (Reading et al., 2007). In in vitro studies human PBMC-derived 
macrophages were shown to secrete IL-18 after inoculation with H3N2 influenza 
virus (Pirhonen et al., 1999). There are, however, no in vivo studies of the kinetics of 
IL-18 during influenza virus infection of humans or experimental animals and the 
reason for the decreased IL-18 levels in our SIV inoculated pigs remains uncertain. 
The proteins of certain viruses like poxviruses or papillomaviruses are known to 
counteract IL-18 by their capacity to bind to it (Xiang and Moss, 1999; Cho et al., 
2001). Another possible way to decrease IL-18 levels is the induction of IL-18 
binding protein (BP) in response to IFN-α, which occurs in chronic hepatitis C 
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patients (Kaser et al., 2002). PBMC-derived human macrophages treated with IFN-α 
were also shown to synthesize less IL-18 protein. Finally, it cannot be excluded that 
concentrations of mature IL-18 are affected by changes in the concentration of ICE, 
which is also involved in the secretion of IL-1β and in apoptosis (Lynch et al., 1997). 
Whatever the reason for the decreased IL-18 levels in our study, our data do not fit 
with a role for IL-18 in the clearance of influenza virus or induction of IFN-γ as has 
been described in the mouse model of influenza (Denton et al., 2007). 
Most cytokines produced during a SIV infection were found at higher levels in 
BALF than in lung homogenates, and only TNF and IFN-γ were detected at similar 
levels in both types of sample. Most important, only the interferons and IL-6 reached 
detectable levels in serum and these were 5 to 100-fold lower than in BALF. These 
findings agree with observations after experimental H1N1 influenza virus infection of 
human volunteers (Hayden et al., 1998). The cytokine responses in plasma or serum 
of these humans were either 100-fold lower than those in nasal lavage fluids, which 
was the case for IL-6 and TNF, or undetectable. Increased plasma levels of various 
cytokines (IL-6, IL-8, IFN-inducible protein 10 (IP-10) and monokine induced by 
IFN-γ (MIG)) have also been reported in very severe cases of human influenza virus 
infection, for example in patients that were hospitalized with human H1N1 influenza 
virus infection (Lee et al., 2007) and in those with highly pathogenic avian H5N1 
influenza virus (Peiris et al., 2004; Gambotto et al., 2008). Local cytokine 
concentrations for those patients were not examined but their plasma levels were 
tightly correlated with viral RNA levels in nasopharyngeal or throat swabs, as well as 
with clinical severity. Though the H5N1 virus may also replicate in non-respiratory 
organs, the lungs or other sites of the respiratory tract are the major site of replication 
and pathology for influenza viruses in mammals. All evidence points towards an 
initial production of cytokines in the lungs and it is accepted that cytokine levels in 
the circulation represent only the spill-over from the respiratory tract. It is logical, 
therefore, that considerable plasma or serum levels are only detectable in “high risk” 
patients with massive virus replication in the respiratory tract and prolonged severe 
illness. This is fully supported by our comparative investigations of BALF, lung 
tissue and serum in pigs. As stated by Openshaw in a paper about cytokine 
measurement in blood samples from SARS patients “The site of sampling, the exact 
time after infection and the method used to measure cytokines are therefore critical 
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determinants with fundamental effects on the interpretation of such studies” 
(Openshaw, 2004). 
APP peaked later than cytokines and, unlike for the cytokines, their levels were 
higher in serum than in BALF. CRP and HG were mainly increased in serum, and to a 
lesser extent in BALF. A rise in serum CRP has been previously reported during 
natural and experimental infection of humans with influenza (Whicher et al., 1985). 
Similarly, increased serum HG levels have been described after experimental 
influenza virus infection of horses (Kent and Goodall, 1991). In contrast to CRP and 
HG, LBP was detected at relatively high levels in the sera of PBS-inoculated control 
pigs, which has also been described by Sachse et al. (2004). Furthermore, the SIV 
infection did not change serum LBP concentrations but caused a rise in BALF LBP. 
The profile of both LBP and HG showed some resemblances with those previously 
observed after experimental infection of CDCD pigs with porcine respiratory 
coronavirus (PRCV) (Van Gucht et al., 2006). The PRCV-infected pigs also had 
constant serum LBP levels and an increase in BALF LBP, while serum HG levels 
peaked later than in SIV-infected pigs. The finding that LBP increases in BALF and 
not in serum suggests that there may be local production of LBP in the lungs besides 
diffusion from the circulation. This hypothesis is supported by some in vitro studies 
(Dentener et al., 2000) in which A549 human epithelial cells produced LBP in 
response to IL-1, IL-6 or TNF. The exact role of APP in viral infections is not yet 
clear. Our APP data agree with the viewpoint that APP induction is a non-specific 
result of circulating cytokines reaching hepatocytes and thus initiating APP 
production. 
In conclusion, influenza viruses appear to induce highly similar profiles of 
cytokines and inflammatory mediators in pigs and humans. Our study remains merely 
descriptive and the mouse model is most suitable to unravel the exact role of specific 
cytokines, because genes for specific cytokines and receptors can be knocked out. On 
the other hand, pigs are natural influenza virus hosts and the pathogenesis of influenza 
in pigs is closer to that in humans. Pigs also show anatomic, physiologic and 
immunologic resemblances to man. For all these reasons, the pig is a valuable animal 
model to examine the therapeutic role of cytokine antagonists during influenza 
infections. 
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Abstract 
 
Cytokines, especially interferon-alpha (IFN-α) are important in controlling 
influenza virus infections. To investigate the role of IFN-α in influenza, the swine 
IFN-α neutralizing monoclonal antibody (Ab) K9 was applied in a swine model of 
influenza A virus infection. First, the optimal dose and route for administration of the 
IFN-α neutralizing Abs was determined. Based on those results, the effect of the Abs 
on a swine influenza virus infection was investigated. Pigs were inoculated 
intratracheally with 106.0 mean egg infectious dose (EID50) A/Swine/Belgium/1/98 
(H1N1) virus. At the time of challenge and 18 hours later, they were injected 
intratracheally and intraperitoneally with a high dose of IFN-α neutralizing Abs or 
control Abs. The animals were euthanized at 0, 24, 30, 48 and 72 h after inoculation. 
At 24 and 30 h, IFN-α levels in broncho-alveolar lavage fluid of K9 recipient animals 
were strongly suppressed, and this coincided with reduced IL-6 and IL-12 levels. TNF 
and IL-1 levels were unaffected compared to those in the control Ab treated group. 
Importantly, the onset and peak of clinical symptoms in IFN-α neutralizing Abs 
treated animals were delayed by 24 hours, simultaneously with the suppression of 
IFN-α, but there was no obvious effect on virus replication and lung pathology. These 
results suggest an important role for IFN-α in IL-6 and IL-12 induction and a role of 
all 3 cytokines in the symptoms of swine influenza. 
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Introduction 
 
Interferons represent a class of evolutionary conserved cytokines that have several 
pathophysiological functions. Most notably, IFNs have potent antiviral activity and 
they are induced in cells upon virus infection. Virus specific RNA (5’ triphosphate 
moieties of single-stranded RNA and double-stranded RNA) is recognized by the cell 
as non-self and initiates interferon production (Bowie and Fitzgerald, 2007). The 
antiviral effect of type I interferon has been extensively studied and works through the 
induction of antiviral proteins (notably protein kinase R (PKR), 2’,5’-oligoadenylate 
synthetase and Mx protein) interfering with viral replication (Haller et al., 2007). 
Interferon-α (IFN-α) is also an important mediator of disease symptoms. It induces 
fever (Dinarello et al., 1984; Kurokawa et al., 1996) and other effects like chills, 
myalgia, malaise, headache and fatigue in healthy human volunteers and cancer 
patients treated with IFN (Scott et al., 1981; Gutterman et al., 1982; Corssmit et al., 
1995). In mice IFN can induce anorexia (Segall and Crnic, 1990). IFN-α also induces 
a transient rise in neutrophil counts in the blood at 8 h post IFN-α injection in human 
volunteers and this effect disappeared at 24 h post injection (Scott et al., 1981; 
Corssmit et al., 1997). These symptoms also occur in typical influenza infections in 
humans and swine and IFN-α is thus considered a key mediator of symptoms in 
influenza (Majde, 2000). 
Influenza in man and pigs is characterized by a profuse production of cytokines. In 
human volunteers inoculated intranasally with influenza, IFN-α, interleukin-6 (IL-6) 
and tumour necrosis factor (TNF) were demonstrated in nasal lavage fluid. The 
increases in IFN-α and IL-6 correlated strongly with each other and with symptoms 
(Hayden et al., 1998). Influenza in pigs can be reproduced by intratracheal (IT) 
inoculation of influenza-naive pigs with a high dose of swine influenza virus (SIV). 
This results in the secretion of IFN-α, IL-6, TNF and IL-1 in broncho-alveolar lavage 
fluid (BALF) (Van Reeth et al., 2002). Similar to humans, IFN-α and IL-6 were the 
most abundantly produced cytokines following SIV infection and their levels 
correlated strongly with each other, virus replication in the lungs and disease 
symptoms (Van Reeth et al., 2002). These results were recently confirmed and 
extended in a study in which we demonstrated a strong up-regulation of additional 
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cytokines (IFN-γ and IL-12) and several acute phase proteins during the acute stage of 
a SIV infection (Barbé et al., 2009). 
Current knowledge on the role of IFN-α in the pathophysiology of influenza has 
been obtained almost entirely from studies in laboratory mice. Much less is known 
about the role of IFN-α in human or swine influenza infection. In older studies in 
laboratory mice IFN-α neutralizing antibodies (Abs) were used. Intravenous 
administration of partially purified sheep anti-mouse interferon globulin in 
intranasally influenza-inoculated mice did not influence the course of disease (Gresser 
et al., 1976). In a later study, in contrast, mice infected with influenza virus by aerosol 
and treated intranasally with a sheep polyclonal anti-interferon serum died within 7 
days post inoculation whereas controls survived. Lung virus titres in IFN-α antiserum 
treated mice were also higher than in controls (Hoshino et al., 1983). These results 
suggest that interferon plays an important role during the early stage of an influenza 
virus infection. More recent studies involved mice deficient in IFN-α/β receptor or 
other proteins involved in the intracellular IFN signalling pathway. Mice lacking the 
signal transducer and activator of transcription 1 (STAT1) protein, which is activated 
when type I or type II IFNs bind to their receptors, were 100-fold more sensitive to 
lethal influenza infection and virus replication was not limited to the respiratory tract 
(García-Sastre et al., 1998). Nevertheless, other studies in the mouse model of 
influenza failed to document a protective role of IFNs. Mice deficient in the IFN-α/β 
receptor were equally susceptible to and had similar lung virus titres than control 
animals upon challenge with X31 (H3N2) virus (Price et al., 2000). The genetic 
background of the mice and the virulence characteristics of the challenge strains may 
in part explain these contradictory findings. 
In this study we used an established model in swine for influenza A virus infection 
and interfered with the type I IFN response by injecting an IFN-α neutralizing 
monoclonal antibody dose at the onset of infection and 18 hours later. This porcine 
IFN-α1 neutralizing mouse monoclonal, designated clone K9, was selected from 
twenty-eight hybridomas and had the highest IFN-α neutralizing capacity (Lefèvre 
and La Bonnardière, 1986; Lefèvre et al., 1990; L'Haridon et al., 1991). The 
availability of this anti-porcine IFN-α neutralizing Ab gave us the unique opportunity 
to investigate the role of IFN-α in swine influenza. Pigs are natural influenza hosts 
and they represent an excellent model to study the pathogenesis of influenza since 
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they show anatomical, physiological and immunological similarities to humans 
(Kuiken and Taubenberger, 2008). We first determined the optimal route and dose of 
administration of the IFN-α neutralizing Abs in a preliminary study. In a second 
experiment we studied the effect of IFN-α neutralizing Abs on several parameters 
(clinical symptoms, lung inflammatory changes, lung virus titres, titres of IFN-α and 
other cytokines in BALF) in caesarean-derived colostrum-deprived (CDCD) pigs 
inoculated with 106 mean egg infectious dose (EID50) H1N1 SIV.  
 
Materials and Methods 
 
Virus and inoculations 
The Swine/Belgium/1/98 (H1N1) SIV strain had been isolated from the lungs of 
fattening pigs during an acute respiratory disease outbreak. The stock used for 
inoculation represented the third egg passage. All virus inoculations were performed 
IT using 106.0 EID50 in 3 ml phosphate-buffered saline (PBS), by inserting a 20-gauge 
needle attached to a syringe in the trachea through the skin cranial to the sternum. The 
Local Ethical Committee of the faculty of Veterinary Medicine, Ghent University 
approved all animal experiments described in this study. 
 
Antibodies and purification 
Neutralizing monoclonal Abs against swine IFN-α derived from hybridoma clone 
K9 were used in this study and have been described earlier (L'Haridon et al., 1991). 
To obtain high enough quantities of K9 antibodies, ascites was produced in mice 
according to standard procedures (Jackson and Fox, 1995). The Federal Public 
Service for health, Food chain safety and Environment approved this procedure. 
Following collection, ascitic fluid was clarified by centrifugation (1 h, 10 000g, 4°C) 
and the antibody fraction was precipitated in 50% ammonium sulphate. The pellet 
fraction was dissolved in 10 mM Tris-HCl pH 8.0 and dialysed against the same 
buffer before loading on a HiPrep DEAE Sepharose Fast Flow column (GE 
Healthcare Europe GmbH, Diegem, Belgium) using an FPLC apparatus (Pharmacia 
Biotech, Uppsala, Sweden). K9 Ab containing fractions were obtained by elution 
using a NaCl gradient and pooled for further use. Monoclonal isotype-matched (IgG1) 
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anti-pseudorabies virus (PRV) antibodies, 13D12 (Nauwynck and Pensaert, 1995), 
were produced and purified in the same way and used as control Abs. 
 
Preliminary experiment to determine the optimal dose and route of administration of 
IFN-α neutralizing Abs 
Four conventional ten-day-old piglets were purchased from a farm and housed in 
HEPA-filtered isolation units and food and water was provided ad libitum. Animals 
received a supplement of milk powder dissolved in water two times a day. 
Three pigs were injected with five million neutralizing units (NU), determined as 
explained further, of IFN-α neutralizing Abs via the intravenous (IV), intraperitoneal 
(IP) or IT route. The remaining pig was first injected IV with five million NU K9 Abs 
and 4 days later with the same dose of the Ab IP. At different time points, blood was 
taken to determine the IFN-α neutralizing Abs titres in serum and pigs were 
euthanised at 6 or 18 h after the last administration of Abs. Euthanasia was performed 
by IV injection of an overdose of sodium pentobarbital 20% (Kela Laboratoria). 
After euthanasia, the entire lung was excised and the right lung was immediately 
lavaged with cold PBS to obtain BALF as described elsewhere (Van Reeth et al., 
1999). BALF was separated into cells and cell-free fluids by centrifugation. Cell-free 
BALF was concentrated 20 times by dialysis against polyethylene glycol, centrifuged 
and used to determine IFN-α neutralizing Abs by an antiviral bioassay as described 
below. Peritoneal fluid of one of the IP treated animals was also examined for the 
presence of K9 IFN-α neutralizing Abs. 
 
IFN-α neutralizing Abs administration in SIV inoculated pigs 
Twenty-two 3-week-old CDCD pigs were used. The pigs originated from four 
sows and were housed in Horsefall-type isolation units with positive-pressure 
ventilation and fed with ultrahigh-temperature-treated cow’s milk supplemented with 
antibiotics. The animals were divided in 3 groups. Two animals were inoculated IT 
with PBS and received no Abs (mock-inoculated). Ten animals were inoculated with 
SIV and received 13D12 isotype-matched control monoclonal Abs (control Abs 
treated). Ten animals were inoculated with SIV and received IFN-α neutralizing 
monoclonal Abs (IFN-α neutralizing Abs treated). 
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Based on the results of the preliminary experiment the IFN-α neutralizing or 
control Abs were administered at the time of SIV inoculation and again 18 h later. At 
both time points the Abs were injected IT and IP at a dose of 10 000 000 NU IFN-α 
neutralizing Abs or an equivalent amount (10 mg) of control Abs. 
The piglets were clinically monitored several times per day from the start of the 
experiment until euthanasia. A clinical score was calculated for each pig. One point 
was assigned for the presence of each of following signs: abdominal thumping, 
dyspnoea, coughing, anorexia and depression. A respiration frequency of 60 - 90 
respirations per minute added 1 point, and > 90 respirations per minute added 2 points 
to the clinical score. Individual clinical scores thus ranged from 0 to 7. 
Both mock-inoculated pigs were euthanised after 24 h. The pigs from the IFN-α 
neutralizing and control Abs treated groups were euthanised at 24 and 30 h (n = 3 per 
group), and 48 and 72 h post inoculation (PI) with SIV (n = 2 per group). Euthanasia 
was performed as described above. 
After euthanasia, the lungs were given a gross lesion score representing an estimate 
of the total lung surface with consolidation. BALF was collected as described above, 
cleared of residual virus and cell debris by centrifugation and used to determine the 
level of IFN-α as well as TNF, IL-1, IL-6 and IL-12. IFN-α was determined using a 
bioassay described below. TNF, IL-1 and IL-6 were assayed using bioassays as 
described earlier (Van Reeth et al., 1999; Van Reeth et al., 2002). Briefly, TNF titres 
were determined in a cytotoxicity test in Porcine Kidney subclone 15 (PK(15)) cells 
and IL-1 activity was measured in a proliferation assay in D10(N4)M cells. IL-6 was 
assayed in a proliferation assay using B9 cells. All bioassays were run two or three 
times and geometric mean titres were calculated. IL-12 was determined with an 
ELISA (Porcine IL-12/IL-23 p40 ELISA (R&D Systems)). The detection limit of this 
test was 18 pg/ml. All samples were tested in duplicate and the ELISA was performed 
as instructed by the manufacturer. Total numbers of BALF cells were counted using a 
Türk chamber. Cytocentrifuge preparations were stained with Diff-Quik® (Medion 
Diagnostics) to determine neutrophil numbers. A pool from the left apical, cardiac and 
diaphragmatic lung lobes was sampled and 20% tissue homogenates were prepared 
for virus titration in Madin-Darby Canine Kidney cells as described previously (Van 
Reeth et al., 2002). Virus titres were calculated using the method of Reed and 
Muench (Reed and Muench, 1938). 
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Quantification of IFN-α and IFN-α neutralizing antibodies 
IFN-α was determined by a bioassay described earlier (Van Reeth et al., 2002). 
Briefly, twofold dilutions of samples were added to Madin-Darby Bovine Kidney 
(MDBK) cells in 96-well plates. Following overnight incubation, cells were 
challenged with vesicular stomatitis virus (VSV) and two days later the antiviral 
effect of the samples was determined. One unit of IFN-α was defined as the reciprocal 
of the dilution producing 50% inhibition of cytopathogenic effect (CPE). Samples 
were tested twice and geometric mean titres were calculated. 
IFN-α-neutralizing antibody titres were determined by a test based on the IFN-α 
bioassay. MDBK cells were seeded in 96-well plates at 25 000 cells per well in 100 µl 
of Dulbecco’s modified Eagle medium with 10% foetal calf serum and antibiotics. 
Following overnight incubation (37°C, 5% CO2) cells were confluent. In a separate 
96-well plate, a twofold dilutions series of samples was made. Next, 5 units (U) of 
recombinant porcine IFN-α in 25 µl medium was added to each well. After 2 h 
incubation at 37°C and 5% CO2, medium was removed from the plate containing 
MDBK cells and dilution series were transferred to the cells. Fifty µl of medium was 
added to each well and after 18 h of incubation (37°C, 5% CO2) cells in sample and 
virus control wells were challenged with 104.8 TCID50 of VSV in 50 µl. Uninfected 
control wells received 50 µl of medium. Two days later, media were removed, and the 
percentage of CPE was determined after staining with neutral red and determining the 
optical density (OD) spectrophotometrically at 492 nm. One NU of IFN-α antibodies 
was defined as the reciprocal of the calculated dilution with 50% CPE. Therefore, the 
following formula was used: 2X (X = exponent of the log 2 dilution with OD just 
below the cut off value + Q). In which the cut off value is the mean OD of virus 
control and uninfected control wells and Q = (cut off value – OD value just below the 
cut off value) / (OD value just above cut off value – OD value just below cut off 
value). Samples were tested twice and geometric mean titres were calculated. 
 
Statistical analysis 
Standard Mann-Whitney tests were used to compare mean clinical scores, virus 
titres and cytokine titres between control Abs and IFN-α neutralizing Abs treated 
groups. Spearman rank correlation coefficients (ρ) were calculated to compare 
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individual IFN-α levels in BALF with other cytokine levels, lung virus titres and 
clinical scores at euthanasia. P < 0.05 was taken as the level of significance. 
 
Results 
 
Preliminary experiment to determine the optimal dose and route of administration of 
IFN-α neutralizing Abs 
Table 1 shows the titres of IFN-α neutralizing Abs in serum, peritoneal fluid and 
BALF at different time points after K9 treatment. Serum IFN-α neutralizing Abs were 
undetectable in all pigs before the first Abs administration, but they were still present 
in the animal that received two K9 injections before the second administration  
(104.0 NU/ml). All routes of administration, except IT, resulted in high and relatively 
constant levels of IFN-α neutralizing Abs (104.3 NU/ml) in serum throughout the 
experiment. IP administration of Abs resulted in up to 103.9 NU/ml in peritoneal fluid 
at euthanasia, 6 h post administration and a persistent level of serum Abs. In the 
BALF, IFN-α neutralizing Abs were only detectable after IT administration. 
Administration of IFN-α neutralizing Abs did not result in clinical symptoms, 
elevated BALF cell levels or neutrophil infiltration in BALF (results not shown). 
 
Effect of IFN-α neutralizing Abs treatment on IFN-α titres in the lungs of SIV 
inoculated pigs 
Figure 1 describes IFN-α levels in BALF at different time points after SIV 
inoculation. In mock-inoculated pigs no IFN-α was present. In control 13D12-Abs 
treated pigs, IFN-α was found at all time points throughout the experiment. IFN-α 
titres peaked at 24 and 30 h PI (21 012 U/ml) and decreased thereafter. By contrast, in 
IFN-α neutralizing Abs treated pigs IFN-α was completely suppressed or only 
marginally present at 24 and 30 h PI. At 48 and 72 h PI, mean IFN-α levels were 
comparable (242 and 3 310 U/ml) to those in control Abs treated pigs (690 and  
2 121 U/ml). 
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Figure 1. Evolution of IFN-α in broncho-alveolar lavage fluid (BALF) of pigs 
inoculated with swine influenza virus and treated with IFN-α neutralizing Abs () or 
control Abs (). Two mock-inoculated control pigs () were euthanized at the start 
of the experiment. Values are expressed as U/ml and geometric means are indicated 
with a horizontal line. The dotted line is the detection limit of the assay. 
 
Effect of IFN-α neutralizing Abs treatment on clinical symptoms, gross lung lesions 
and lung inflammatory changes in SIV inoculated pigs 
Next we evaluated clinical parameters and lung inflammation in the infected 
animals. Mock-inoculated animals did not show symptoms, had no lung lesions and 
displayed only marginal neutrophil infiltration in BALF. Figure 2 shows the evolution 
of the clinical scores in control Abs and IFN-α neutralizing Abs treated pigs. The 
control Abs treated animals showed respiratory and general symptoms that started to 
develop at 21 h PI, peaked at 30 h PI and resolved at 48 h PI. At 30 h PI, 3 out of 4 
animals showed symptoms and the mean clinical score was 2.25. Until 24 h PI, IFN-α 
neutralizing Abs treated animals were free of symptoms. General and respiratory 
symptoms increased thereafter and peaked at 48 h PI with a mean clinical score of 
2.75. At 72 h PI, 1 of the 2 IFN-α neutralizing Abs treated pigs still showed an 
increased respiration rate (80 respirations per minute) and abdominal thumping. 
Clinical symptoms were thus delayed compared to control Abs treated pigs. 
Table 2 shows gross lung lesions (% consolidation of lung surface), number of 
cells in BALF, neutrophil and mononuclear cell infiltration in BALF. In control Abs 
treated animals, consolidation of the lung increased gradually from 1 to 7% 
throughout the experiment. The number of neutrophils and mononuclear cells in 
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BALF peaked at 24 and 30 h PI and bordered baseline levels again at 48 and 72 h PI. 
In IFN-α neutralizing Abs treated pigs consolidation of the lung surface gradually 
increased from 1% at 24 h PI to 28% at 72 h PI. The number of BALF neutrophils 
peaked also at 24 and 30 h PI and bordered baseline levels again at 72 h PI. At 48 h PI 
neutrophil and mononuclear cell levels were slightly higher compared to control 
animals. 
 
 
Figure 2. Evolution of clinical scores in pigs inoculated with swine influenza virus 
and treated with IFN-α neutralizing Abs () or control Abs (). Values are means  
(+ standard error of the mean). * represents statistically significant difference  
(P < 0.05) between IFN-α neutralizing Abs treated and control Abs treated pigs. 
 
 
Effect of IFN-α neutralizing Abs treatment on lung virus titres in SIV inoculated pigs 
Lungs of mock-inoculated pigs were free of virus (data not shown). Figure 3 
describes lung virus titres at different time points after SIV inoculation. In control 
Abs treated pigs virus titres reached 109 mean tissue culture infectious dose (TCID50) 
per gram at 24 and 30 h PI with SIV. At 48 and 72 h PI, when clinical symptoms had 
subsided, virus titres were about 100 times lower. In IFN-α neutralizing Abs treated 
pigs, lung virus titres followed the same profile and only differed at 48 h PI when they 
were 101.8 times higher compared to those in control animals. 
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Figure 3. Virus titres in lung tissue homogenates of swine influenza virus inoculated 
pigs treated with IFN-α neutralizing Abs () or control Abs (). Mock-inoculated 
pigs were free of virus. The dotted line is the detection limit. 
 
Effect of IFN-α neutralizing Abs treatment on IL-6, TNF, IL-12 and IL-1 titres in 
BALF of SIV inoculated pigs 
IL-6, TNF, IL-12 and IL-1 levels in BALF were determined at different time points 
PI and are depicted in figure 4. All 4 cytokines were undetectable in mock-inoculated 
pigs. Control Abs treated pigs showed peak levels of all four cytokines at 24 or 30 h 
PI. At later time points, these cytokine titres dropped or became undetectable. The 
IFN-α neutralizing Abs treated pigs displayed increased levels of all four cytokines 
starting at 24 h PI but levels of IL-6 and IL-12 were lower compared to control Abs 
treated pigs at 24 h PI, although without statistically significant difference. In 
addition, peak levels of IL-6 and IL-12 were reached at 48 h PI in IFN-α neutralizing 
Abs treated pigs. At 48 and 72 h PI cytokine levels were comparable to those in 
control Abs treated pigs. 
 
Correlations between parameters 
Table 3 shows correlations between IFN-α titres and the cytokines measured in 
BALF, lung virus titres and clinical scores in control or IFN-α neutralizing Abs 
treated animals. In control animals, IFN-α correlated significantly with IL-6, IL-12, 
TNF, IL-1 and lung virus titres but not with the clinical scores. In IFN-α neutralizing 
Abs treated animals IFN-α only correlated significantly with IL-12 and the correlation 
between IFN-α and IL-6 was not significant (ρ = 0.23; P = 0.53). 
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Table 3. Spearman rank correlation coefficient (ρ) between IFN-α in broncho-
alveolar lavage fluid (BALF) and other cytokines, lung virus titres and clinical scores 
in control animals or animals treated with IFN-α neutralizing Abs. 
Correlation of IFN-α with IFN-α 
neutralizing 
Abs 
IL-6 IL-12 TNF IL-1 Virus Clinical score 
- 0.77 0.86 0.94 0.88 0.86 n.s.(1) 
+ n.s. 0.81 n.s. n.s. n.s. n.s. 
(1) not significant (P ≥0.05) 
 
 
Discussion 
 
This study aimed to investigate the role of IFN-α in a SIV infection by treatment 
with porcine IFN-α neutralizing monoclonal Abs. Using this approach we could 
efficiently suppress IFN-α in BALF during the first 30 h after SIV infection, but  
IFN-α was again detectable at later time points. Because of the limited number of 
animals in this study, lung virus titres or BALF cytokine levels did not reach 
statistically significant differences between control and IFN-α neutralizing Abs 
treated pigs at specific time points. When data from all animals over the complete 
period of investigation were cumulated, however, IFN-α and IL-6, but not TNF, IL-1 
or IL-12 were significantly lower in IFN-α neutralizing Abs treated animals. Clinical 
symptoms were clearly delayed in the animals treated with IFN-α neutralizing Abs. 
This study strongly points towards a role for IFN-α in induction of IL-6, IL-12 and 
disease symptoms. 
The first part of this study focussed on the determination of an optimal route and 
dose of exogenously administered IFN-α neutralizing Abs. Administration of IFN-α 
neutralizing Abs via the IP, IT or IV route did not cause any adverse reactions to the 
pigs and resulted in detectable and long lasting levels of IFN-α neutralizing activity in 
serum. Intraperitoneal administration seemed to have a depot effect that can be 
advantageous when IFN-α levels need to be suppressed for an extended period. 
Intratracheal administration was the only way to reach detectable levels of Abs in 
BALF, which contains massive amounts of IFN-α in SIV infected pigs (Van Reeth et 
al., 2002). In contrast with IP or IV administration, IT administration resulted in only 
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low levels of Abs in the circulation. Therefore, we decided to administer IFN-α 
neutralizing Abs both via the IP and IT route in the principal experiment. 
IL-6 and to a lower extent IL-12 were reduced until 30 h PI in IFN-α neutralizing 
Abs treated pigs whereas there was no effect on TNF and IL-1. Some of our 
observations are in line with previous studies. Subcutaneous injection of human 
volunteers with IFN-α resulted in the induction of IL-6 without effects on TNF and 
IL-1β levels (Corssmit et al., 1995; Corssmit et al., 1997). These data fit very well 
with our study where treatment with IFN-α neutralizing Abs reduced IL-6 titres at the 
early time points after infection. In contrast with our findings, IFN-α appears to 
inhibit the production of IL-12 in mice in vitro and in vivo. In vitro addition of IFN-α 
to murine splenic leucocytes reduced the IL-12 inducing capacity of Staphylococcus 
aureus and IFN-α/β neutralizing Abs treated mice had higher levels of IL-12 after 
inoculation with murine cytomegalovirus (Cousens et al., 1997). Both in the present 
and in a previous study (Barbé et al., 2009) we found a strong correlation between 
IFN-α on the one hand and IL-6 and IL-12 on the other, suggesting a biological 
connection between these cytokines. Difference in IFN-α levels between control and 
IFN-α neutralizing Abs treated groups are certainly the most likely explanation for 
the differences in IL-6, IL-12 and clinical symptoms, because there were no 
differences in virus titres. Other studies have reported that IFN-α is not involved in 
the induction of IL-1 or TNF, which fits with our study (Corssmit et al., 1995; 
Corssmit et al., 1997). 
The peak of clinical symptoms in IFN-α neutralizing Abs treated pigs was delayed 
to later time points (from 30 to 48 h PI), as was the detection of IFN-α in BALF. This 
strongly suggests a role for IFN-α in the induction of disease, reminiscent of the 
situation in human influenza infections and in human IFN-α recipients, as postulated 
before by other researchers (Scott et al., 1981; Majde, 2000). Body temperatures were 
not monitored in the current experiment since this was incompatible with the housing 
of piglets in sterile conditions. Still, our unpublished preliminary data demonstrated 
an effect of IFN-α neutralization on the development of fever. It must be taken in 
account, however, that the effects of IFN-α neutralization on the symptoms of 
influenza may be indirect through suppression of IL-6 and IL-12. 
It is difficult to judge to what extent IFN-α has an antiviral effect in our SIV 
infection model. The untreated pigs had extremely high lung virus titres at 24 and 30 
Chapter 4 
_____________________________________________________________________ 
104 
h PI, together with high IFN-α titres, followed by a drop in virus titres at 48 and 72 h 
PI. At 48 h PI, the IFN-α neutralizing Abs treated pigs clearly had higher lung virus 
titres than the controls. Type I IFNs mediate their antiviral effects through the 
induction of antiviral proteins, which could explain the lack of an antiviral effect 
during the first 30 h PI. On the other hand, the minimal differences between IFN-α 
neutralizing and control Abs treated pigs question as to whether IFN-α has significant 
antiviral activity against SIV under the present experimental conditions. It is known 
that some influenza viruses can partially escape from the antiviral activity of IFN by 
the action of their NS1 protein, which binds viral dsRNA that is required for the 
activation of the IFN-induced antiviral protein PKR (Lu et al., 1995). NS1 deleted 
swine influenza viruses may be useful to determine whether this may happen during 
SIV infection. 
It is a challenge to neutralize the extremely high amounts of IFN-α produced 
during a SIV infection by antibody treatment, and to obtain high antibody levels 
locally in the lungs where IFN-α is produced. These difficulties most likely account 
for the fact that we could suppress IFN-α only temporarily. Still, the use of IFN-α 
neutralizing antibodies has allowed us to study the effect of IFN-α during the earliest 
stage of infection. Knock-out animals for cytokine receptor genes are very difficult to 
construct in domestic animal species like swine, and we do not consider IFN-α 
receptor gene knock-out pigs a realistic alternative. Furthermore, the interpretation of 
the effects of a single cytokine will always be hampered by the redundancy of the 
cytokine network, whatever approach one uses to block specific cytokines. 
In conclusion, exogenously administered IFN-α neutralizing Abs can suppress 
IFN-α in the pig lung during the very acute stage of a swine influenza virus infection. 
Although this strategy had a clear effect on IFN-α levels in the lungs, the suppression 
of IFN-α was only temporal. Despite an obvious delay in the onset of clinical signs, 
lung virus titres, symptoms and lung pathology were at least as severe as those in the 
control Abs treated group at 48 and 72 h PI when IFN-α and other cytokines were no 
longer reduced. Our data indicate a role for IFN-α in IL-6 and IL-12 induction and for 
a role of all 3 cytokines in the symptoms that are associated with swine influenza. 
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General discussion and future perspectives 
 
Infections with swine influenza virus (SIV) in pigs lead to typical “flu” symptoms 
and the production of proinflammatory cytokines. This has been well documented 
before (Van Reeth et al., 1998; Van Reeth et al., 1999; Van Reeth et al., 2002). 
Despite extensive knowledge about the pathology and disease signs of influenza, the 
understanding of the disease mechanisms is still incomplete. 
The first part of the thesis focussed on the use of commercially available ELISAs 
as an alternative for the currently used hemagglutination inhibition (HI) test for the 
detection of SIV specific antibodies (Abs) against European SIVs. A second goal of 
the research in this thesis was to describe in more detail the response of cytokines and 
acute phase proteins in SIV inoculated pigs and also to specifically investigate the 
role of interferon-α (IFN-α) in the pathogenesis of swine influenza. A caesarean-
derived colostrum-deprived (CDCD) pig model was used for this aim because this 
eliminates possible interference with background levels of cytokines due to other 
infections (Van Reeth et al., 1998).  
Three different SIV subtypes are endemic in swine populations worldwide and 
there are antigenic differences between the same SIV subtypes on different continents 
(Olsen et al., 2006). With the increasing number of novel subtypes and genetic 
variants, especially in North America in the last decade, the epidemiology of SIV 
became more and more complex (Vincent et al., 2008). Consequently, serology for 
SIV is complicated and may require different antigens in the HI test in different 
regions of the world. Less work intensive and commercially available techniques such 
as enzyme-linked immunosorbent assay (ELISA) are available for the detection of 
antibodies against SIV. Most of these kits are of American origin and have only been 
validated for the detection against the SIV strains circulating in North America. 
Because SIV in America and Europe are antigenically different they will induce 
antibodies that recognize other epitopes. An implication of this fact is that it is not 
recommended to use ELISAs validated for America in Europe without additional 
validation. This is especially important for ELISAs based on a whole virus or the 
hemagglutinin (HA), which have a high antigenic variability, as a coating antigen.  
In Chapter 3 of this thesis the IDEXX H1N1 and H3N2 ELISA were validated for 
the first time with well-defined sera from swine experimentally infected or vaccinated 
with European SIV isolates. The results of these ELISAs were compared with the 
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currently used “gold standard” for the detection of antibodies against SIV, the HI test. 
The latter test is relatively laborious but its advantages are that it is sensitive, subtype 
and strain specific. The comparison showed that these ELISAs have a low sensitivity 
and that the ELISAs frequently fail to detect antibodies against European SIVs. It can 
be expected that other ELISA systems of American origin based on the HA or the 
whole virus will not perform better. A lesson from these data is that ELISA systems 
based on the HA of SIV need to be validated separately in different regions of the 
world. Another option for the detection of antibodies against SIV by ELISA is the use 
of a species and subtype unrestricted test with the nucleoprotein (NP) of the virus as a 
coating antigen (Kim et al., 2006). These kits were developed for the detection of 
avian influenza in poultry. This virus is normally absent in industrially reared poultry 
and consequently the detection of antibodies would be sufficient for diagnosis of 
influenza. In contrast, swine influenza is endemic and an at least four-fold rise in NP 
antibody levels between acute and convalescent serum would be necessary for the 
diagnosis of a recent SIV infection. To our knowledge, the feasibility of such an 
approach for diagnosis of swine influenza has not yet been investigated. Another 
disadvantage is that detection of NP antibodies gives no information about the 
subtype or antigenic characteristics of the virus. Up to now, an at least four-fold 
increase in HI titre between acute and convalescent serum in at least one of three 
separate HI tests with an avian-like H1, a human-like H1 and an H3 is still the method 
of choice for serological diagnosis of swine influenza. 
In Chapter 4.1 we investigated the course of interleukin-12 (IL-12), IFN-γ and  
IL-18 in a SIV infection. We chose these cytokines because 1) swine specific ELISAs 
are available for these molecules and 2) IL-12 and IFN-γ are proinflammatory 
cytokines and IL-18 is supposed to be an IFN-γ inducing factor. Chapter 3.1 indicates 
that a plethora of cytokines and also acute phase proteins (APP), which were already 
well investigated in the course of bacterial diseases, are probably involved in the 
pathogenesis of swine influenza. This hypothesis is based on the fact that there is a 
very strong correlation between titres of cytokines in broncho-alveolar lavage fluid 
(BALF) such as IFN-α, tumour necrosis factor (TNF), IL-1, IL-6, IL-12 and IFN-γ 
with virus replication and disease. Peak levels of these cytokines were found at 24-30 
h post inoculation (PI) concurrent with maximal disease symptoms. Levels of these 
cytokines were much higher in BALF compared to serum. This has been 
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demonstrated before by other researchers (Hayden et al., 1998) and suggests that 
cytokines are locally produced at the site of inflammation. Indeed, lung macrophages 
are very good producers of many cytokines after infection with influenza virus 
(Cheung et al., 2002). Cytokines might have more local than systemic effects and 
cytokines present in the circulation after a respiratory infection probably represent 
only a spill over from the inflamed tissue (Openshaw, 2004), which might be in part 
due to an increased permeability of the blood vessels in the inflamed tissue.  
One of the newly investigated cytokines, namely IL-18, did not follow the classic 
pattern with a peak at 24-30 h PI of SIV. It was present in BALF and serum of 
uninoculated control pigs and IL-18 levels decreased after inoculation of SIV and 
returned to basal levels at the end of the infection. IL-18 is expressed as a precursor 
molecule intracellularly and the IL-1β converting enzyme (ICE) cleaves it into mature 
IL-18 and it is afterwards released from the cell. The ELISA used in this research 
certainly detects the mature form of IL-18 since the standard of the kit is a 
recombinant mature Escherichia coli expressed IL-18 protein. This does not exclude 
that the kit is also able to detect the pro-IL-18 molecule. A possible way to investigate 
this is to perform a western blot on BALF, lung tissue and serum samples to check 
whether the size of the IL-18 molecule matches with the size of the precursor form 
(24 kDa) or the mature form (20 kDa) of IL-18. Some viruses, such as poxviruses or 
papillomaviruses, can bind IL-18 and thus they counteract the IL-18 (Xiang and 
Moss, 1999; Cho et al., 2001). Another possible explanation for the decrease in IL-18 
is the induction of an IL-18 binding protein by IFN-α as occurs in chronic hepatitis C 
patients (Kaser et al., 2002). This possibility can be further investigated by examining 
the IL-18 levels in the BALF of IFN-α neutralizing Abs treated pigs. Higher IL-18 
levels in BALF of such pigs than in non-treated pigs would indicate that IFN-α 
induces the production of an IL-18 binding protein. 
In contrast with cytokines, the role of APP in viral infections is largely unknown. 
APP are a very heterogeneous group of plasma proteins whose levels rise during 
inflammatory processes. In this thesis it was also investigated whether APP might 
play a role in the pathogenesis of an influenza infection. Thereto levels of different 
APP, namely haptoglobin (HG), lipopolysaccharide (LPS) binding protein (LBP) and 
C-reactive protein (CRP) in BALF and serum of SIV inoculated pigs were 
determined. APP levels rose, particularly in serum and less in BALF. APP peaked 
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later than cytokines, which is an indication that APP are induced by cytokines as is 
generally accepted (Moshage et al., 1988; Murch, 1998). Higher levels of LBP and 
HG in serum compared to BALF and a peak of APP that falls later than the cytokine 
peak was also found earlier in porcine respiratory coronavirus (PRCV) inoculated 
CDCD piglets (Van Gucht et al., 2006). The role of APP in the pathogenesis of 
influenza remains unclear. It is however known that increased CRP levels are seen in 
influenza patients (Falsey et al., 2001; Melbye et al., 2004). It is therefore more 
logical to postulate that production of APP during a SIV infection is a side effect of 
the spill over of cytokines from the lungs to the circulation, from where they reach the 
liver and consequently induce APP as is seen in many bacterial infections (Murch, 
1998). For some APP like LBP a local production in lung epithelial cells might also 
be possible since its levels in BALF rose more than in serum (Dentener et al., 2000). 
The above-described correlations are not a proof that these cytokines or APP are 
involved in the pathogenesis of swine influenza. Thereto cytokine or APP suppressing 
therapies have to be applied in SIV inoculated animals. The effect of IFN-α in swine 
influenza was investigated in Chapter 4.2 where porcine IFN-α neutralizing 
monoclonal antibodies were used to unravel the role of IFN-α in the pathogenesis of 
swine influenza. 
Previous investigations on the effect of proinflammatory mediators in the 
pathogenesis of porcine respiratory diseases such as porcine reproductive and 
respiratory syndrome virus (PRRSV) disease involved the cytokine inhibitors 
pentoxyfilline (a phosphodiesterase inhibitor), and the prostaglandin inhibitors 
meloxicam and flunixin meglumine (Van Gucht et al., 2004). Pentoxyfilline 
suppresses TNF production in pigs (Gibson et al., 1991) and the other two molecules 
are non-steroidal anti-inflammatory drugs that suppress cyclo-oxygenase production 
and these are registered for use in swine. A porcine model for multifactorial 
respiratory disease in pigs was used (Van Gucht et al., 2004). In that model the 
inoculation of PRRSV or LPS, a cell wall component of Gram-negative bacteria, 
induces only a subclinical to mild disease whereas the subsequent inoculation of 
PRRSV and LPS has a synergistic effect on symptoms and cytokine production. Only 
pentoxyfilline reduced BALF levels of the cytokines TNF and IL-1 after dual 
inoculation with PRRSV and LPS. The two other inhibitors of proinflammatory 
mediators had no effect on levels of proinflammatory cytokines in BALF after 
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PRRSV-LPS inoculation. Other investigators also concluded that pentoxyfilline is a 
moderate inhibitor of proinflammatory mediators in a swine model for acute lung 
inflammation caused by Actinobacillus pleuropneumoniae (Myers et al., 2002). This 
led to the conclusion that these inhibitors are not adequate tools to study the role of 
proinflammatory cytokines in the pathogenesis of porcine respiratory diseases 
because 1) their cytokine suppressing capacity is insufficient and 2) they have a 
pleiotropic effect. Consequently, more specific cytokine inhibitors, such as antibodies, 
are needed for such research. These findings inspired us to use monoclonal porcine 
IFN-α neutralizing antibodies (Abs) to investigate the role of IFN-α in the 
pathogenesis of a SIV infection. With this approach it was possible to suppress IFN-α 
during the first 48 hours of a SIV infection. This suppression of IFN-α correlated with 
a reduction in IL-6 and IL-12 levels and thus IFN-α might be an in vivo stimulus for 
the production of IL-6 and IL-12. This hypothesis can be supported by literature 
findings. After infection of epithelial cells with influenza virus, these cells produce 
and release IFN-α. This cytokine triggers leucocytes to produce endogen pyrogens 
such as IL-1, IL-6, IL-12 and TNF (Brydon et al., 2005). It is thus logical that lower 
IFN-α levels result in reduced levels of IL-6 and IL-12. The onset and peak of clinical 
symptoms in SIV inoculated and IFN-α neutralizing Abs treated animals were 
delayed by 24 h. This finding agrees very well with a mouse model of influenza in 
which IFN type I receptor knock-out mice had less symptoms early in the infection 
whereas symptoms were exacerbated later on in the infection (Traynor et al., 2007). 
In our experimental animal model there was most likely also an effect on the body 
temperature. Previous unpublished data from our group showed a delayed induction 
of fever in SIV inoculated and IFN-α neutralizing Abs treated pigs and these animals 
also had reduced IL-6 levels in BALF. This strongly feeds the hypothesis that IFN-α 
and IL-6 are strong inducers of fever and disease symptoms occurring in the field 
after influenza infections in pig herds. 
Several studies reported a significant increase in proinflammatory cytokines, a so-
called cytokine storm, in severe cases of seasonal influenza, lethal H5N1 and 
probably also in Mexican flu infections in humans (Peiris et al., 2004; Lee et al., 
2007; Gambotto et al., 2008). The syndrome of acute respiratory distress and 
multiple-organ failure is probably related to this cytokine dysregulation (Beigel et al., 
2005). There is scientific interest whether inhibition of the inflammatory cytokine 
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response might offer a lifesaving therapy for humans. However, mice deficient in the 
inflammatory cytokines TNF or IL-6 had similar morbidity and mortality as wild-type 
mice, and it might therefore be preferable to develop therapies that target the virus 
rather than cytokines in severe cases of influenza (Salomon et al., 2007). 
The approach used in the thesis is very promising for the investigation of the role 
of specific cytokines in the pathogenesis of various diseases. On the other hand, the 
anti-cytokine strategy is not suitable for treatment of an acute infection such as 
influenza in swine or humans. The brisk appearance of cytokines, the high cost to 
produce anti-cytokines antibodies and the redundancy of the effect of different 
cytokines are reasons that hamper a timely and efficient suppression of the effects of 
proinflammatory cytokines. Moreover, cytokines are necessary for the development 
of a good immune response against the invading pathogen. Other cytokine inhibitors 
that could be used are for example etanercept (Enbrel®), which binds TNF, or 
anakinra (Kineret®), an IL-1 receptor antagonist. These molecules relieve symptoms 
in chronic inflammatory processes where there is a relatively mild cytokine 
production such as in rheumatoid arthritis in humans. Experiments with Enbrel® in 
PRCV inoculated pigs reduced TNF levels in BALF but had no effect on other 
cytokines, disease symptoms or virus titres (Atanasova et al., 2009). A combination 
of different cytokine antagonists in SIV inoculated pigs, for example IFN-α and 
Enbrel®, might have a bigger effect than the use of only one of the components 
separately because there is a very tight interplay between cytokines and they stimulate 
each others production. 
IFN-α is a cytokine that links the innate and adaptive immunity (Price et al., 2000; 
Le Bon et al., 2001; Tough, 2004). IFN-α plays an important role for the transition 
from an innate to an adaptive immune response (Brassard et al., 2002). This transition 
to the more efficient and specific adaptive immune response is critical to clear the 
invading pathogen. Other cytokines such as TNF and IL-12 are also supposed to link 
the innate and the adaptive immunity (Belardelli and Ferrantini, 2002). Different 
mechanisms by which IFN-α could modulate the adaptive immune system were 
described. IFN-α is a differentiation and maturation factor for antigen-presenting 
dendritic cells and consequently IFN-α is a strong adjuvant for the immune response 
(Tough, 2004). Subcutaneous injection of IFN-α augments antibody production and 
induced isotype switching upon antigen stimulation and this indicates that IFN-α 
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enhances immune responses in vivo (Le Bon et al., 2001; Brassard et al., 2002). 
Besides enhancing the primary response, IFN-α was also able to induce long-term 
antibody production after a single injection of antigen (Le Bon et al., 2001). It would 
be interesting to investigate whether IFN-α suppression would have an effect on the 
specific antibody development and on the cell mediated immune response in SIV 
inoculated pigs. 
As a general conclusion we can state that commercial ELISAs for the detection of 
antibodies against North American SIVs need to be validated thoroughly before they 
can be used for diagnosis of swine influenza in other regions of the world. We also 
created a model for the evaluation of the role of specific cytokines in the pathogenesis 
of swine influenza and we could prove the pivotal role of IFN-α in the pathogenesis 
of a SIV infection in an in vivo experiment. The experimental animal model used in 
the present thesis can be used in the future to test the role of other cytokines in the 
pathogenesis of swine influenza or other porcine respiratory viruses. 
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Summary 
 
Swine influenza viruses (SIVs) of three different subtypes are enzootic in swine 
producing regions worldwide. Pigs can be used as a valuable animal model for the 
study of influenza in humans because the disease and pathology show many 
resemblances with influenza in humans.  
 
In Chapter 1 an introduction to influenza viruses and the pathogenesis of a SIV 
infection is given. The different options for the serological diagnosis of swine 
influenza are also summarized. Finally, the introduction summarizes the current 
knowledge about the cytokine response, with the emphasis on interferon-α (IFN-α), 
after a swine influenza virus infection.  
 
The aims of the thesis are outlined in Chapter 2. A first major aim was to 
investigate whether commercially available enzyme-linked immunosorbent assays 
(ELISA) can be used for the detection of antibodies against European SIVs. The 
second aim was to investigate in more detail the response of cytokines and acute 
phase proteins (APP) after a SIV infection, and to study the role of IFN-α in the 
pathogenesis of swine influenza. 
 
In Chapter 3 it was examined whether a commercial ELISA could serve as an 
alternative for the currently used gold standard for the serological diagnosis of swine 
influenza, the hemagglutination inhibition (HI) test. Several ELISAs are on the 
market. They are often of American origin and since influenza viruses differ 
antigenically between North America and Europe, a validation is necessary before 
these tests can be used for the diagnosis of swine influenza in Europe. We tested the 
capacity of two ELISAs, the IDEXX Swine Influenza Virus H1N1 ELISA and the 
IDEXX Swine Influenza Virus H3N2 ELISA, to detect antibodies against European 
SIVs. For this purpose, we used sera from piglets that were singly inoculated with 
European H1N1, H1N2 or H3N2 SIV; piglets consecutively inoculated with two SIV 
subtypes; piglets vaccinated with commercial European SIV vaccines; or piglets 
inoculated with H1N1 and/or H3N2 SIV followed by a single vaccination with a 
commercial SIV vaccine. These different possibilities mimic the complex 
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epidemiological situation of swine influenza at the farm level where animals can be 
infected with one ore more SIV subtypes, where different farms can use different 
vaccines and where vaccinated animals could have undergone previous infections 
with SIV. Serum samples of all pigs were collected bi-weekly for 4 to 8 weeks after 
inoculation or vaccination. All sera were tested by HI tests and IDEXX ELISAs. 
Sera of animals vaccinated with commercial SIV vaccines and sera of animals that 
were experimentally infected with a European H1N1 SIV were often negative in the 
H1N1 ELISA although they were generally clearly positive in the HI test. Vaccination 
of animals that had undergone a previous infection with SIV had very high antibody 
titres in the H1N1 HI test and these animals were also positive in the H1N1 ELISA. 
The overall relative sensitivity and specificity of the IDEXX Swine Influenza Virus 
H1N1 ELISA was 39% and 99%, respectively. 
The H3N2 ELISA yielded largely the same results. Only a limited number of 
animals that were positive in the H3N2 HI test were positive in the H3N2 ELISA. 
Mostly these animals had high HI antibody titres. The overall relative sensitivity and 
specificity of the IDEXX Swine Influenza Virus H3N2 ELISA was 35% and 97%, 
respectively. 
The data showed that the ELISAs frequently failed to identify pigs infected with 
European SIVs or vaccinated with commercial European vaccines. Pigs that were 
positive in the ELISA generally had very high HI antibody titres. The poor sensitivity 
of the ELISAs may be due to antigenic differences between the SIV strains in the test 
kits and the strains used for inoculation or vaccination. The HI test thus remains the 
method of choice for the detection of serum antibodies against SIV although subtype-
unrestricted ELISAs based on the conserved influenza virus nucleoprotein (NP) might 
be an alternative. 
 
Chapter 4 of the thesis extends our knowledge about cytokines and APP in a SIV 
infection. Chapter 4.1 offers a detailed description of the cytokine and APP response 
in broncho-alveolar lavage fluid (BALF), serum and lung homogenates of SIV 
inoculated piglets. To this purpose caesarean-derived colostrum-deprived (CDCD) 
piglets were intratracheally (IT) inoculated with 107.5 EID50 Swine/Belgium/1/98 
(H1N1) SIV. Piglets were euthanized at 24, 30, 48, 72 and 120 h post inoculation 
(PI). Two more piglets were mock-inoculated and served as controls. After 
euthanasia, BALF, serum and lung tissue were collected. The cytokines IFN-α, 
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interleukin-1 (IL-1), IL-6 and tumour necrosis factor (TNF) were determined by 
bioassays whereas IFN-γ, IL-12 and IL-18 were determined by ELISAs. Cytokines 
were determined in BALF, serum and lung tissue. The APP C-reactive protein (CRP), 
haptoglobin (HG) and lipopolysaccharide binding protein (LBP) were determined by 
ELISA or colorimetric assay in both BALF and serum. All cytokines, except IL-18, 
were undetectable in mock-inoculated animals and peaked in all three compartments 
(BALF, serum and lung tissue) at 24 or 30 h PI. Cytokine levels in BALF were 10 to 
100-fold higher than in lung tissue or serum, respectively. At 120 h PI, levels of all 
cytokines returned to baseline levels. IL-18 levels were lower at 24 and 30 h PI than 
at 0 h PI and they increased thereafter. The APP CRP and HG peaked 24 h later than 
the cytokines and reached higher levels in serum than in BALF, while LBP rose in 
BALF only. Lung virus titres were tightly correlated with BALF IFN-α, IL-6, IL-1, 
TNF, IFN-γ and IL-12, as well as with serum levels of IL-6 and the interferons. The 
strongest correlations were found between virus titres and IFN-α and IL-6 in BALF. 
IL-18 was negatively but not significantly correlated with other parameters. Disease 
was correlated with the same cytokines in BALF and in serum, as well as with BALF 
LBP and serum CRP. 
We concluded that most investigated cytokines play a role in the pathogenesis of 
swine influenza. The reason for the aberrant behaviour of IL-18 in a SIV infection 
needs further investigation. APP appear to be cytokine induced since peak levels of 
APP are reached at a later time point than peak levels of cytokines. Influenza viruses 
appear to induce similar profiles of cytokines and inflammatory mediators in pigs and 
humans. Swine may thus be a valuable experimental animal model for the study of the 
pathogenesis of influenza. 
 
In Chapter 4.2 the specific role of IFN-α in the pathogenesis of swine influenza 
was investigated. For this purpose swine IFN-α neutralizing monoclonal antibodies 
(Abs) were used. 
First, the optimal dose and route for administration of the IFN-α neutralizing Abs 
was determined. For that purpose, conventional piglets were injected with IFN-α 
neutralizing Abs at a dose of five million neutralizing units (NU) via the intravenous 
(IV), intraperitoneal (IP) or IT route. At different time points post administration, 
blood was taken to determine the IFN-α neutralizing Abs titres in serum and pigs 
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were euthanized at 6 or 18 h after administration of Abs. All routes of administration, 
except IT, resulted in high and relatively constant levels of Abs in serum throughout 
the experiment. IP administration of Abs resulted in detectable levels of Abs in 
peritoneal fluid at euthanasia, and a persistent level of serum Abs. In the BALF,  
IFN-α neutralizing Abs were only detectable after IT administration. 
Next, the effect of IFN-α neutralizing antibodies on the pathogenesis of a SIV 
infection was investigated. Two CDCD piglets were mock-inoculated and served as 
controls. Twenty CDCD piglets were inoculated IT with 106.0 EID50 
Swine/Belgium/1/98 (H1N1) SIV. Based on the results of the first part of the 
experiment, ten pigs were injected IT and IP with 10 million NU IFN-α Abs at the 
time of virus inoculation and 18 h later. The remaining ten pigs received an irrelevant 
control Ab. Piglets were euthanized at 24, 30, 48 and 72 h PI. Lung tissue was 
collected for virus titration and BALF for the determination of cytokines. At 24 and 
30 h, IFN-α levels were strongly suppressed in BALF of animals that received IFN-α 
neutralizing antibodies, and this coincided with reduced IL-6 and IL-12 levels. TNF 
and IL-1 levels were unaffected compared to those in the control Ab treated group. 
Importantly, the onset and peak of clinical symptoms in IFN-α neutralizing Abs 
treated animals were delayed by 24 hours, simultaneously with the suppression of 
IFN-α, but there was no obvious effect on virus replication and lung pathology. 
Intraperitoneally and IT administered IFN-α neutralizing Abs can temporarily 
suppress IFN-α in the pig lung which is produced during the very acute stage of a 
swine influenza virus infection. Together with this suppression, there was an obvious 
delay in the onset of clinical signs, IL-6 and IL-12 in BALF. On the other hand, lung 
virus titres and lung pathology were at least as severe as those in the control Abs 
treated group. Our data indicate a role for IFN-α in IL-6 and IL-12 induction and a 
role for all 3 cytokines in the symptoms that are associated with swine influenza. 
 
In conclusion, we can state that commercial ELISAs for the detection of antibodies 
against North American SIVs need to be evaluated thoroughly before they can be 
used for diagnosis of swine influenza in other regions of the world. In this thesis a 
model for the evaluation of the role of specific cytokines in the pathogenesis of swine 
influenza was also created. It was also demonstrated that IFN-α plays a paramount 
role in the pathogenesis of swine influenza. The experimental animal model used in 
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the present thesis can be further used in the future to test the role of other cytokines in 
the pathogenesis of swine influenza or other porcine respiratory viruses. 
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Samenvatting 
 
Drie verschillende subtypes van varkensinfluenza virussen zijn wereldwijd 
enzoötisch aanwezig in regio’s met intensieve varkenshouderij. Varkens kunnen 
gebruikt worden als een waardevol model voor de studie van influenza bij mensen 
aangezien het ziekteverloop en de pathologie van varkensinfluenza vele gelijkenissen 
vertoont met influenza bij de mens. 
 
In Hoofdstuk 1 wordt een inleiding gegeven op influenzavirussen en de 
pathogenese van een varkensinfluenza virus infectie. De verschillende technieken 
voor de serologische diagnose van varkensinfluenza worden ook samengevat. 
Tenslotte vat de inleiding de huidige kennis samen over de cytokine respons, met de 
nadruk op interferon-α (IFN-α), ten gevolge van een varkensinfluenza virus infectie. 
 
De doelstellingen van de thesis worden vermeld in Hoofdstuk 2. Een eerste 
belangrijke doelstelling was om na te gaan of commercieel beschikbare enzyme-
linked immunosorbent assays (ELISAs) gebruikt kunnen worden voor de detectie van 
antistoffen tegen Europese varkensinfluenza virussen. De tweede doelstelling was het 
in meer detail onderzoeken van de respons van cytokines en acute fase eiwitten na een 
varkensinfluenza virus infectie, en om de rol van IFN-α in de pathogenese van 
varkensinfluenza na te gaan. 
 
In Hoofdstuk 3 werd onderzocht of een commercieel beschikbare ELISA een 
alternatief kan vormen voor de huidige gouden standaard voor de serologische 
diagnose van varkensinfluenza, de hemagglutinatie inhibitie (HI) test. Verschillende 
ELISAs zijn commercieel beschikbaar. Deze zijn dikwijls van Amerikaanse 
oorsprong en aangezien influenzavirussen antigenisch verschillen tussen Noord-
Amerika en Europa, is een validatie nodig vooraleer deze testen gebruikt kunnen 
worden voor de diagnose van varkensinfluenza in Europa. We testten de capaciteit 
van twee ELISAs, de IDEXX Swine Influenza Virus H1N1 ELISA en de IDEXX 
Swine Influenza Virus H3N2 ELISA, voor het opsporen van antistoffen tegen 
Europese varkensinfluenza virussen. Hiervoor gebruikten we sera van biggen die 
enkel werden geïnoculeerd met een Europees H1N1, H1N2 of H3N2 
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varkensinfluenza virus; biggen die achtereenvolgens werden geïnoculeerd met twee 
varkensinfluenza subtypes; biggen gevaccineerd met in Europa beschikbare 
varkensinfluenza virus vaccins; of biggen geïnoculeerd met een H1N1 en/of H3N2 
varkensinfluenza virus gevolgd door een enkele vaccinatie met een commercieel 
varkensinfluenza virus vaccin. Deze verschillende mogelijkheden reflecteren de 
complexe epidemiologische situatie van varkensinfluenza op bedrijfsniveau, waar 
dieren kunnen geïnfecteerd zijn met één of meerdere influenzavirus subtypes, waar 
verschillende bedrijven verschillende vaccins kunnen gebruiken en waar dieren die 
gevaccineerd worden eerdere infecties met varkensinfluenza virus kunnen hebben 
ondergaan. Serum stalen van alle varkens werden tweewekelijks verzameld 
gedurende 4 tot 8 weken na inoculatie of vaccinatie. Alle sera werden getest met HI 
testen en de IDEXX ELISAs. 
Sera van dieren die gevaccineerd werden met commercieel beschikbare 
varkensinfluenza virus vaccins en sera van dieren die experimenteel geïnfecteerd 
werden met een Europees H1N1 varkensinfluenza virus waren dikwijls negatief in de 
H1N1 ELISA. Vaccinatie van dieren die een eerdere infectie met varkensinfluenza 
virus ondergaan hadden, hadden zeer hoge antistoftiters in de H1N1 HI test en deze 
dieren waren ook positief in de H1N1 ELISA. De totale relatieve sensitiviteit en 
specificiteit van de IDEXX Swine Influenza Virus H1N1 ELISA was respectievelijk 
39% en 99%. 
De H3N2 ELISA gaf over het algemeen hetzelfde beeld. Enkel een beperkt aantal 
dieren die positief waren in de H3N2 HI test waren positief in de H3N2 ELISA. 
Meestal hadden deze dieren een hoge HI antistoftiter. De totale relatieve sensitiviteit 
en specificiteit van de IDEXX Swine Influenza Virus H3N2 ELISA was 
respectievelijk 35% en 97%. 
De resultaten tonen aan dat de ELISAs dikwijls tekort schoten om varkens te 
detecteren die geïnfecteerd waren met Europese varkensinfluenza virussen of 
gevaccineerd waren met commerciële Europese vaccins. Varkens die positief waren 
in de ELISA hadden over het algemeen een zeer hoge HI antistoftiter. De zwakke 
gevoeligheid van de ELISAs kan te wijten zijn aan antigenische verschillen tussen de 
varkensinfluenza stammen gebruikt in de ELISA en de stammen gebruikt voor 
inoculatie of vaccinatie. De HI test blijft dus de voorkeursmethode voor het opsporen 
van serum antistoffen tegen varkensinfluenza virussen alhoewel niet-subtype 
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specifieke ELISAs, gebaseerd op het geconserveerde nucleoproteïne van het 
influenzavirus, mogelijk een alternatief kunnen vormen. 
Hoofdstuk 4 van deze thesis handelt over cytokines en acute fase eiwitten tijdens 
een varkensinfluenza virus infectie. Hoofdstuk 4.1 biedt een gedetailleerde 
beschrijving van de cytokine en acute fase eiwitten respons in broncho-alveolaire 
lavage (BAL) vloeistof, serum en long homogenaten van varkensinfluenza virus 
geïnoculeerde biggen. Hiervoor werden gnotobiotische biggen intratracheaal (IT) 
geïnoculeerd met 107.5 EID50 Swine/Belgium/1/98 (H1N1) varkensinfluenza virus. 
Biggen werden geëuthanaseerd op 24, 30, 48, 72 en 120 h post inoculatie (PI). Twee 
bijkomende controlebiggen werden geïnoculeerd met fosfaatgebufferde zoutoplossing 
(FGZ). Na euthanasie werden BAL vloeistof, serum en longweefsel verzameld. De 
cytokines IFN-α, interleukine-1 (IL-1), IL-6 en tumor necrose factor (TNF) werden 
bepaald met biologische testen terwijl IFN-γ, IL-12 en IL-18 bepaald werden met 
ELISAs. Cytokines werden bepaald in BAL vloeistof, serum en longweefsel. De 
acute fase eiwitten C-reactief proteïne (CRP), haptoglobine (HG) en 
lipopolysaccharide-bindend proteïne (LBP) werden bepaald met een ELISA of een 
colorimetrische test in zowel BAL vloeistof als serum. Alle cytokines, met 
uitzondering van IL-18, waren niet detecteerbaar in controlevarkens en piekten in de 
drie compartimenten (BAL vloeistof, serum en longweefsel) op 24 en 30 h PI. 
Cytokine gehaltes in BAL vloeistof waren 10 tot 100 maal hoger dan in 
respectievelijk longweefsel of serum. De gehaltes van alle cytokines keerden terug 
naar hun basale niveaus op 120 h PI. De concentratie van IL-18 was lager op 24 en 30 
h PI dan op 0 h PI en nam vervolgens terug toe. De acute fase eiwitten CRP en HG 
piekten 24 h later dan de cytokines en bereikten hogere gehaltes in serum dan in BAL 
vloeistof, terwijl LBP enkel in BAL vloeistof steeg. Virustiters in de long waren sterk 
gecorreleerd met IFN-α, IL-6, IL-1, TNF, IFN-γ en IL-12 in BAL vloeistof, en ook 
met serum gehaltes aan IL-6 en interferonen. De sterkste correlaties werden gevonden 
tussen virustiters en IFN-α en IL-6 in BAL vloeistof. IL-18 was negatief maar niet 
significant gecorreleerd met andere parameters. Ziekte was gecorreleerd met dezelfde 
cytokines in BAL vloeistof en serum als virustiters, en ook met LBP in BAL vloeistof 
en CRP in serum. 
We concludeerden dat de meeste onderzochte cytokines een rol spelen in de 
pathogenese van varkensinfluenza. De reden voor het afwijkende gedrag van IL-18 in 
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een varkensinfluenza virus infectie dient verder onderzocht te worden. Acute fase 
eiwitten lijken geïnduceerd te worden door cytokines aangezien de piek gehaltes aan 
acute fase eiwitten op een later tijdstip bereikt worden dan deze van de cytokines. 
Influenzavirussen lijken een zelfde profiel aan cytokines en ontstekingsmediatoren te 
induceren bij varkens als bij mensen. Varkens kunnen dus een waardevol diermodel 
zijn voor de studie van de pathogenese van influenza bij de mens. 
 
In Hoofdstuk 4.2 werd specifiek de rol van IFN-α in de pathogenese van 
varkensinfluenza nagegaan. Hiervoor werden varkens IFN-α neutraliserende 
monoclonale antistoffen (As) gebruikt. 
Ten eerste werd de optimale dosis en toedieningsweg van de IFN-α 
neutraliserende As bepaald. Hiervoor werden conventionele biggen geïnjecteerd met 
vijf miljoen neutraliserende eenheden (NE) IFN-α As via de intraveneuze (IV), 
intraperitoneale (IP) of IT weg. Op verschillende tijdstippen na toediening werd bloed 
genomen voor het bepalen van de IFN-α neutraliserende As titer in serum, en de 
varkens werden geëuthanaseerd op 6 of 18 h na toediening van de As. Alle 
toedieningswegen, met uitzondering van de IT, resulteerden in hoge en relatief 
constante As gehaltes in serum gedurende het experiment. IP toediening van de As 
resulteerde in detecteerbare gehaltes van de As in peritoneale vloeistof bij euthanasie, 
en een persistent gehalte aan serum As. In BAL vloeistof waren IFN-α As enkel 
detecteerbaar na IT toediening. 
Vervolgens werd het effect nagegaan van de toediening van IFN-α neutraliserende 
As op de pathogenese van een varkensinfluenza virus infectie. Twee gnotobiotische 
varkens werden als controledieren gebruikt. Twintig andere gnotobiotische varkens 
werden IT geïnoculeerd met 106.0 EID50 Swine/Belgium/1/98 (H1N1) 
varkensinfluenza virus. Gebaseerd op de resultaten van het eerste deel van het 
experiment werden 10 varkens IT en IP geïnjecteerd met 10 miljoen NE IFN-α As op 
het moment van virus inoculatie en ook 18 h later. De 10 overblijvende varkens 
werden geïnjecteerd met een irrelevante controle As. De biggen werden 
geëuthanaseerd op 24, 30, 48 en 72 h PI. Longweefsel werd verzameld voor 
virustitratie en BAL vloeistof werd verzameld voor de bepaling van cytokines. Op 24 
en 30 h PI was het gehalte aan IFN-α in BAL vloeistof van dieren die IFN-α 
neutraliserende As kregen sterk onderdrukt, en dit viel samen met verlaagde IL-6 en 
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IL-12 gehaltes. TNF en IL-1 gehaltes werden niet beïnvloed in vergelijking met deze 
in de controle As behandelde groep. Een belangrijke observatie was dat het begin en 
de piek van klinische symptomen bij IFN-α neutraliserende As behandelde dieren 
werd uitgesteld met 24 h, tezamen met de onderdrukking van IFN-α, maar er was 
geen duidelijk effect op virusvermeerdering en longpathologie. 
Intraperitoneaal en IT toegediende IFN-α neutraliserende As kunnen het IFN-α dat 
geproduceerd wordt tijdens het hyperacute stadium van een varkensinfluenza virus 
infectie in de long van varkens tijdelijk onderdrukken. Samen met deze 
onderdrukking was er een duidelijke vertraging in het opkomen van klinische 
symptomen en IL-6 en IL-12 in BAL vloeistof. Anderzijds waren virustiters in de 
long en longpathologie minstens zo uitgesproken als in de controle As behandelde 
groep. Onze resultaten wijzen er op dat IFN-α een rol speelt in inductie van IL-6 en 
IL-12 en wijzen op een rol voor deze drie cytokines in het ontwikkelen van de 
symptomen die gepaard gaan met varkensinfluenza. 
 
Als conclusie kunnen we stellen dat commerciële ELISAs voor het opsporen van 
antistoffen tegen Noord-Amerikaanse varkensinfluenza virussen grondig moeten 
gevalideerd worden voor ze kunnen gebruikt worden voor de diagnose van 
varkensinfluenza in andere regio’s van de wereld. In deze thesis werd ook een model 
ontwikkeld voor het onderzoeken van de rol van specifieke cytokines in de 
pathogenese van varkensinfluenza. Er werd ook aangetoond dat IFN-α een zeer 
belangrijke rol speelt in pathogenese van varkensinfluenza. Het diermodel dat 
gebruikt werd in de huidige thesis kan verder gebruikt worden in de toekomst voor 
het testen van de rol van andere cytokines in de pathogenese van varkensinfluenza of 
andere respiratoire virussen. 
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Zes jaar geleden begon mijn “carrière” aan het Laboratorium voor Virologie. In die 
periode heb ik van velen steun, raad en hulp gekregen. Nu ik het labo verlaten heb 
past het deze mensen even te bedanken. Mijn eerste woord van dank gaat uit naar 
mijn promotor, Prof. Van Reeth. De afgelopen zes jaar zijn snel voorbij gegaan en 
gedurende die periode heb ik de kans gekregen om veel bij te leren, en dit doctoraat 
tot een goed einde te brengen. Prof. Nauwynck wil ik zeker ook bedanken. We 
hebben regelmatig van gedacht gewisseld over bioveiligheid, nieuw te bouwen 
stallen, ... De kennis die ik tijdens deze discussies heb opgedaan zal me zeker nog van 
pas komen. Ook prof. Favoreel verdient een woord van dank. Je was altijd bereid om 
met raad en daad mee te werken aan de verwezenlijking van dit doctoraat. 
Gedurende de afgelopen zes jaar zijn er veel mensen in het labo bijgekomen of 
weg gegaan. Eerst wil ik degenen die het labo verlaten hebben vernoemen. Geoffrey, 
jij was de eerste die me geholpen heeft bij de varkensexperimenten. Steven, je bent 
niet alleen lid van de examencommissie van dit doctoraat maar je hebt me ook altijd 
veel wetenschappelijke inzichten bijgebracht. Peter M was eveneens zeer behulpzaam 
tijdens de eerste jaren van mijn verblijf in het labo. Peter D wil ik ook bedanken voor 
de hulp bij de initiële stappen van de IFN-α antistof opzuivering, waar ik geen kaas 
van gegeten had. Ook Karen wil ik bedanken voor de hulp bij het geven van de 
practica, wat niet evident is als pas afgestudeerde. Ook was je een aangenaam 
gezelschap in het bureau. Chris, je geniet nu van een welverdiend pensioen en hebt 
me dikwijls geholpen met PBMC’s te isoleren, antistofverdunningen klaar te maken, 
en zo veel meer. Ook het op maandag oplossen van de quiz uit de weekendkrant was 
een leuke verpozing.  
Els en Hannah, jullie waren de oprichtsters van de FIP groep. Sinds enige tijd is 
die uitgebreid met nieuw bloed, Evelien, Leslie en Ben. Ook aan de allernieuwste 
mensen in de groep, Dominique en Annelike, die dit jaar hun IWT moeten verdedigen 
wens ik veel succes. Ik duim mee. 
Aangezien je in het labo snel “oud” wordt, heb ik verschillende mensen zien 
komen, die reeds voor mij andere horizonten hebben opgezocht. David, ik hoop dat je 
nieuwe werk je bevalt en vond de samenwerking met jouw altijd zeer aangenaam. 
Ann D, An S, Gerald, Meezanur en Constantinos: ook voor jullie wens ik dat de 
toekomst veel goeds mag brengen. 
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Gedurende mijn verblijf in het labo ben ik altijd aan dezelfde bureau blijven zitten 
maar zijn de mensen om me heen regelmatig van plaats gewisseld. Annick en 
Annelies, we zaten ongeveer vier jaar samen in ons bureautje, en hebben ons daar 
goed geamuseerd, net zoals op de buiten-labo activiteiten. Bij dit laatste mag ik zeker 
Sarah G en Barbara niet vergeten. Tijdens de laatste maand kreeg ik dan plots ander 
gezelschap in het bureau. Annebel, jouw doctoraat loopt ook bijna ten einde en ik 
hoop dat je spoedig een leuke job vind. Sjouke, je was niet alleen mijn nieuwe buur 
maar je neemt ook de assistent-verantwoordelijkheden over. Wat het betekent om 
practica te geven zal je spoedig mogen ondervinden. 
Werken in een labo was voor mij zes jaar geleden een volledig onbekende wereld. 
Lieve, bijna al mijn kennis over labovaardigheden heb ik van jouw geleerd, waarvoor 
ik je zeer dankbaar ben. Ook Chantal en Carine hebben me regelmatig geholpen met 
experimenten of de voorbereiding van practica. Nele, jij bent enkele maanden na mij 
gestart op het labo, eerst als stagiaire en je bent nadien op het labo gebleven. Je hebt 
me ook steeds met vele zaken uit de brand geholpen als er weer eens antistoffen 
dienden opgezuiverd te worden of voor het uitvoeren van titraties en zo veel meer. Je 
immer opgewekte verschijning was een positieve noot. Melanie, ook jouw wil ik 
bedanken voor alles wat je de laatste jaren voor mij gedaan hebt. Je hebt ontelbare 
keren (of toch ongeveer 200 keer) MDBK en B9 cellen gesplitst, flesjes en potjes 
voor practica gevuld en zo veel meer. Ook Dries wil ik bedanken voor de Western 
blots die hij onlangs nog heeft uitgevoerd. Bij de dierproeven waren er altijd twee 
present: Geert en Fernand. Fernand, je carrière aan de unief loopt ook op zijn laatst. Je 
praktische vaardigheden met varkens zijn legendarisch en hebben je al eerder de naam 
varkensfluisteraar opgeleverd. Geert, jij was altijd op de meest onmogelijke uren en 
dagen present voor swabs of bloed te nemen en varkens te transporteren. 
Ook degenen die meer moleculair werk verrichten (Celine, Gerlinde, Hanne, Inge, 
Iris, Karen, Matthias, Merijn, Miet, Natasha, Nick, Nina, Wander,) en degenen waar 
ik minder met heb samengewerkt (Dipongkor, João, Lennert, Mathias, Sabrina, 
Uladzimir) wil ik ook bedanken voor het gezelschap de afgelopen jaren. Kalina, I 
hope that you’ll be able to finish your PhD soon and that you will find a nice job. Ook 
administratieve en computerondersteuning waren de afgelopen jaren regelmatig nodig 
en daarvoor wil ik Gert, Mieke en Dirk bedanken. 
Een speciaal woord van dank gaat ook naar Debby die een hele tijd mijn meest 
naaste collega is geweest met het interferon werk. Debby, het zag er naar uit dat we 
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elk een andere professionele richting insloegen maar het lot heeft er voor gezorgd dat 
we nu beide in de pluimvee wereld zijn beland en bijgevolg zullen we elkaar zeker 
nog tegen komen en met elkaar samen werken. Ook met degenen die ’s middags 
trouw mee gingen eten, en dan zeker aan Sarah C en Marc, wil ik hier nog eens 
speciaal een dank u zeggen voor al het plezier dat we dan beleefd hebben. 
Op het einde van dit doctoraat wil ik tenslotte nog mijn ouders zeker bedanken. 
Ook mijn vriendin, Elise, ben ik dankbaar voor alle steun de afgelopen maanden. De 
toekomst ziet er goed uit! 
 
